预约演示
更新于：2026-06-17
Emtricitabine
恩曲他滨
更新于：2026-06-17
概要
基本信息
药物类型 小分子化药 |
别名 (2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone、(−)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine、(−)-2'-deoxy-5-fluoro-3'-thiacytidine + [18] |
靶点 |
作用方式 抑制剂 |
作用机制 RT抑制剂(逆转录酶抑制剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2003-07-02), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C8H10FN3O3S |
InChIKeyXQSPYNMVSIKCOC-NTSWFWBYSA-N |
CAS号143491-57-0 |
关联
162
项与 恩曲他滨 相关的临床试验NCT03304717
Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome
The overall objectives are to explore the safety and efficacy of Reverse Transcriptase Inhibitors Tenofovir (TDF)/ Emtricitabine (FTC) administered in AGS affected children 2 to 18 years of age.
开始日期2025-12-01 |
申办/合作机构 |
NCT07062614
Exploration of Intra-individual Variability of Exposure to Emtricitabine and Lamivudine in Hair With a View to Validating the Value of This Matrix as a Diagnostic Tool for Partial and/or Total Non-compliance With Antiretroviral Treatment
Treatment adherence is defined by compliance with the dosage schedule (i.e., dose per dose and number of doses per day), as well as the duration of administration (i.e., number of days during which the dosage schedule must be followed).
Treatment adherence determines the therapeutic efficacy and the absence of toxicity of the prescribed medication. However, this adherence is far from being respected even by patients with serious pathologies such as patients living with HIV (PLWHIV). However, among PLWHIV, non-adherence is a significant source of virological failure and is difficult to assess because it is most often based on what the patient reports to their doctor. A currently used approach consists of determining the drug concentration in the blood and possibly that of its metabolite(s). However, determining a drug's blood concentration presents two major pitfalls: (i) it is necessary to take a blood sample, which remains an invasive procedure for the patient; (ii) for the vast majority of drugs, if the patient scrupulously adheres to the dosage schedule a few days before the blood sample is taken, the drug concentration is most often within the expected range. Therefore, a concentration in the reference range does not exclude partial or even total non-compliance between two medical visits. Saliva is a more easily accessible matrix than blood. However, the same representativeness problem is encountered due to the fact that saliva is in almost instantaneous equilibrium with blood.
Urine could be used to assess compliance. However, this requires multiple urine collections between two doses. This constraint is not compatible with the organization of clinical services. The objective is to determine intra-individual variability in the amount of antiretroviral (ARV) in different segments of the same strand of hair during periods of full treatment adherence.
This objective is preliminary to the use of hair as a tool for detecting treatment non-adherence in patients.
Two reference antiretroviral molecules will be documented: Emtricitabine and Lamivudine, as they are present, one or the other, in the majority of antiretroviral combination strategies.
Treatment adherence determines the therapeutic efficacy and the absence of toxicity of the prescribed medication. However, this adherence is far from being respected even by patients with serious pathologies such as patients living with HIV (PLWHIV). However, among PLWHIV, non-adherence is a significant source of virological failure and is difficult to assess because it is most often based on what the patient reports to their doctor. A currently used approach consists of determining the drug concentration in the blood and possibly that of its metabolite(s). However, determining a drug's blood concentration presents two major pitfalls: (i) it is necessary to take a blood sample, which remains an invasive procedure for the patient; (ii) for the vast majority of drugs, if the patient scrupulously adheres to the dosage schedule a few days before the blood sample is taken, the drug concentration is most often within the expected range. Therefore, a concentration in the reference range does not exclude partial or even total non-compliance between two medical visits. Saliva is a more easily accessible matrix than blood. However, the same representativeness problem is encountered due to the fact that saliva is in almost instantaneous equilibrium with blood.
Urine could be used to assess compliance. However, this requires multiple urine collections between two doses. This constraint is not compatible with the organization of clinical services. The objective is to determine intra-individual variability in the amount of antiretroviral (ARV) in different segments of the same strand of hair during periods of full treatment adherence.
This objective is preliminary to the use of hair as a tool for detecting treatment non-adherence in patients.
Two reference antiretroviral molecules will be documented: Emtricitabine and Lamivudine, as they are present, one or the other, in the majority of antiretroviral combination strategies.
开始日期2025-07-03 |
申办/合作机构 |
NCT07210528
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Emtricitabine and Descovy in Patients With Mild Cognitive Impairment.
Recent studies have identified an association between Alzheimer's Disease (AD) and an expansion of DNA content in the brain (prefrontal cortex). This additional DNA content appears to be derived from reverse transcriptase (RT) activity that incorporates genomic cDNAs (gencDNAs) into chromosomes, resulting in multiple copies of full length and shorter cDNAs involving many genes - including the causal AD gene amyloid precursor protein (APP). Accumulation of these APP gencDNAs is associated with AD.
This identifies RT as a promising therapeutic target for the attenuation of AD progression through existing reverse transcriptase inhibitors (RTi's) that have been widely used for treating HIV and hepatitis B. Since this class of drugs has been in the clinic for over 3 decades, there are significant data supporting their post-approval safety for long-term use. However, this has not been specifically addressed in the target population - patients with mild cognitive impairment (MCI), particularly women - who are underrepresented in HIV datasets.
This proposed Phase I safety trial will perform a Special Population Study in a cohort of MCI patients who may benefit from the intervention.
This study aims to (1) evaluate the safety and tolerability of standard dose FTC or Descovy for 3 months in MCI patients; (2) as secondary aims, collect preliminary data on clinical effects of standard dose FTC or Descovy compared to placebo for 3 months on cogntiive function in MCI patients; and (3) collect preliminary data on clinical effects of standard dose FTC or Descovy compared with placebo on AD-associated inflammatory markers.
Participants will be randomized into either Descovy or FTC arms in equal numbers, and receive either active drug or placebo. Participants will orally ingest 1 capsule or tablet (depending on drug arm) daily for the 3 month participation period.
The investigators hypothesise that MCI are not at increased risk of adverse effects due to administration of standard dose FTC or Descovy.
This identifies RT as a promising therapeutic target for the attenuation of AD progression through existing reverse transcriptase inhibitors (RTi's) that have been widely used for treating HIV and hepatitis B. Since this class of drugs has been in the clinic for over 3 decades, there are significant data supporting their post-approval safety for long-term use. However, this has not been specifically addressed in the target population - patients with mild cognitive impairment (MCI), particularly women - who are underrepresented in HIV datasets.
This proposed Phase I safety trial will perform a Special Population Study in a cohort of MCI patients who may benefit from the intervention.
This study aims to (1) evaluate the safety and tolerability of standard dose FTC or Descovy for 3 months in MCI patients; (2) as secondary aims, collect preliminary data on clinical effects of standard dose FTC or Descovy compared to placebo for 3 months on cogntiive function in MCI patients; and (3) collect preliminary data on clinical effects of standard dose FTC or Descovy compared with placebo on AD-associated inflammatory markers.
Participants will be randomized into either Descovy or FTC arms in equal numbers, and receive either active drug or placebo. Participants will orally ingest 1 capsule or tablet (depending on drug arm) daily for the 3 month participation period.
The investigators hypothesise that MCI are not at increased risk of adverse effects due to administration of standard dose FTC or Descovy.
开始日期2025-06-30 |
申办/合作机构 |
100 项与 恩曲他滨 相关的临床结果
登录后查看更多信息
100 项与 恩曲他滨 相关的转化医学
登录后查看更多信息
100 项与 恩曲他滨 相关的专利（医药）
登录后查看更多信息
5,775
项与 恩曲他滨 相关的文献（医药）2026-12-31·ANNALS OF MEDICINE
Efficacy and metabolic outcomes of switching from an INSTI-based triple-drug regimen to dolutegravir/lamivudine in treatment-experienced HIV-1-infected patients: a 48-week real-world study
Article
作者: Li, Qisui ; Zhang, Wei ; Yuan, Jing ; Deng, Changgang
BACKGROUND:
Real-world data on switching from INSTI-based triple therapy to DTG/3TC in the Chinese population are lacking.
METHODS:
This retrospective study included 214 treatment-experienced patients with HIV from Chongqing Public Health Medical Center (2021-2022) on an INSTI-based triple-drug regimen for ≥6 months who switched to DTG/3TC for >12 months. Patients with pre-existing metabolic diseases were excluded. Participants were categorized: INSTI+TAF-free (n = 100, prior TDF/AZT/ABC), INSTI+TAF (n = 56, prior BIC/FTC/TAF), and INSTI+TAF+COBI (n = 58, prior EVG/c/FTC/TAF). Virological, immunological, and metabolic parameters were assessed at weeks 24 and 48.
RESULTS:
The INSTI+TAF+COBI group was significantly older (p=0.000). Virological suppression rates (<50 copies/mL) were high at switch (93%, 85.7%, 91.4%). The INSTI+TAF+COBI group had lower eGFR and higher TG, TC, HDL, and LDL at baseline (p < 0.05). After switching, virological suppression remained high (≥90%) at weeks 24 and 48. CD4+ T-cell increases showed no significant intergroup differences. Metabolic changes differed: TC changes were 0.57 mmol/L (IQR: -0.19-0.91) in INSTI+TAF-free, -0.09 mmol/L (-0.47-0.71) in INSTI+TAF, and -0.25 mmol/L (-0.99-0.33) in INSTI+TAF+COBI. LDL changes were 0.23 mmol/L (-0.23-0.67), -0.15 mmol/L (-0.39-0.01), and -0.18 mmol/L (-0.71-0.10), respectively. TC and LDL changes differed significantly among groups (p < 0.05).
CONCLUSION:
Switching to DTG/3TC maintained virological suppression and stable immunological outcomes. Patients previously on TAF-containing regimens demonstrated greater metabolic benefits than those on TAF-free regimens, possibly related to baseline TDF effects, requiring further confirmation.
2026-08-01·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial
Article
作者: Barrado-Cuchillo, Julia ; Navarrete-Lorite, Miguel Nicolas ; Corona Mata, Diana ; Rivero, Antonio ; Mican Rivera, Rafael ; Tiraboschi, Juan ; Gil, Pedro ; Velasco Arribas, Maria ; de la Fuente Moral, Sara ; Ferreira Tata, Claudia ; Rivero Juarez, Antonio ; Perez-Valero, Ignacio ; Ryan, Pablo ; Perez Stachowski, Xavier ; Crussells Canales, María Jose ; Garcia Fraile, Lucio Jesus ; Mena de Cea, Alvaro ; Molero Bonilla, Marta ; Artigues Serra, Francisca ; Diaz Almidon, Mariana
OBJECTIVE:
To evaluate if switching from dolutegravir/lamivudine (DTG/3TC) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) improves neuropsychiatric tolerability in suppressed adults with stable neuropsychiatric comorbidities.
METHODS:
MIND was a phase IV, randomised, double-blind, multicentre trial. Participants were assigned (1:1) to switch to BIC/FTC/TAF or continue DTG/3TC. The primary endpoint was the proportion of grade 2-4 neuropsychiatric adverse events (NP-AEs) at week 24. Secondary endpoints included safety, virological maintenance, and patient-reported outcomes (PROs) through week 48.
RESULTS:
Eighty participants were randomised (BIC/FTC/TAF, n = 41; DTG/3TC, n = 39). At week 24, grade 2-4 NP-AEs occurred in 14.6% of the BIC/FTC/TAF arm vs 17.9% in the DTG/3TC group (difference: 3.3% [95%CI -19.5 to 12.9]; P = 0.688). At week 48, incidences were 21.9% vs 17.9% (difference: 4.0% [95%CI -13.5 to 21.5]; P = 0.650). NP-AE-related discontinuations were low (7.3% vs 5.1%). At week 24, BIC/FTC/TAF showed less moderate-to-severe nausea/vomiting (3.8% vs 23.2%; P = 0.027) and abdominal discomfort (16.8% vs 40.2%; P = 0.04). At week 48, BIC/FTC/TAF reported more headache (55.7% vs 26.1%; P = 0.03) but fewer skin symptoms (24.9% vs 49.2%; P = 0.022). All maintained virological suppression at week 48; four participants on DTG/3TC met failure criteria but achieved re-suppression without emergent resistance. PRO trajectories and treatment satisfaction remained high and stable throughout the study, with no significant between-group differences.
CONCLUSIONS:
In PLWH with stable neuropsychiatric comorbidities, switching to BIC/FTC/TAF did not reduce NP-AEs or improve PROs versus continuing DTG/3TC. Both regimens were safe and highly effective at maintaining virological suppression through 48 weeks.
TRAIL NUMBER:
NoEUDRACT:2021-005927-19.
2026-08-01·ENVIRONMENTAL POLLUTION
Simulated freeze–thaw cycles restructure plastisphere microbiomes and functional gene co-occurrence networks in alpine lake sediment microcosms
Article
作者: Bo, Zhong ; Ruixi, Liu ; Xintong, Mei ; Naying, Li ; Yixin, He ; Xin, Liu ; Xiaofeng, Wang ; Wei-Min, Wu ; Shaoliang, Yi ; Li, Zhou ; Honghui, Lin
Microplastics (MPs) are increasingly recognized as dynamic ecological interfaces rather than inert contaminants, yet their role in shaping microbial functional interactions under climate-driven disturbances remains poorly understood. In particular, how climate driven freeze-thaw cycles (FTCs) influence the dynamics of mobile genetic elements (MGEs) within the plastisphere remains unclear. Here, we used controlled microcosms containing sediments from Tibetan Plateau lakes and polyethylene/polyethylene terephthalate particles to examine how simulated extreme FTCs were associated with changes in plastisphere microbial communities and functional gene co-occurrence patterns. FTCs reshaped plastisphere microbial communities, but their assembly trajectories differed between habitats. In the plastisphere, deterministic selection was pronounced at early FTC stages, whereas it did not further intensify with increasing FTC frequency. In contrast, sediment communities exhibited a progressive shift toward deterministic assembly with increasing FTCs. Concomitantly, MGEs were relatively enriched in the plastisphere and co-occurrence with genes involved in carbon metabolism, antibiotic resistance genes (ARGs), and virulence factors (VFs), forming interconnected functional networks. Notably, FTCs were associated with the enrichment of specific carbon metabolizing taxa (e.g., Comamonas and Brevundimonas) within the plastisphere that also carried relatively high abundances of MGEs, ARGs, and VFs. These patterns suggest that MPs may provide ecological niches linking carbon utilization and gene exchange potential. Collectively, this work highlights the interactive influence of climate-related disturbance and emerging pollutants on plastisphere microbial ecology, and provides a mechanistic basis for future assessment of ecological implications in fragile alpine ecosystems.
574
项与 恩曲他滨 相关的新闻（医药）2026-06-14
下面是2026年6月8日至2026年6月14日这一周国际头部药企（top30）的国际审批、合作授权、收并购、临床进展及财务业绩情况
国际审批方面：
强生：6月9日，强生旗下DePuy Synthes宣布，搭载人工智能辅助功能的VELYS髋关节导航系统正式在美国上市。依托VELYS中枢平台，可自动解析影像、精准定位解剖标志点、可自动完成影像判读与标志点识别，针对患者个体输出下肢长度、偏心距、髋臼假体位置的实时量化参考数据，提升手术流程效率，优化全髋关节置换术的诊疗。
强生：6月11日，强生宣布，正在美国扩大最新一代老花矫正型人工晶状体（PC‑IOL）的上市覆盖范围。TECNIS PureSee人工晶状体属于景深延长型（EDOF）人工晶体，可为接受白内障手术的患者带来清晰、优质的视觉体验。
罗氏：6月11日，罗氏宣布，美国FDA已受理其递交的阿替利珠单抗（泰圣奇，Tecentriq，atezolizumab）及阿替利珠单抗透明质酸酶（Tecentriq Hybreza）联合化疗，用于III期DNA错配修复缺陷（dMMR）/高度微卫星不稳定（MSI-H）结肠癌辅助治疗的补充生物制品许可申请。FDA已授予该项申请优先审评资格。申请依据ATOMIC研究数据，研究成果近期已刊发于《新英格兰医学杂志》。结果显示，对于经VENTANA MMR伴随诊断免疫组化试剂盒等检测确认为dMMR型III期结肠癌患者，在标准FOLFOX6（氟尿嘧啶、奥沙利铂、亚叶酸钙疗法）化疗基础上加用阿替利珠单抗，可将疾病复发或死亡风险相对降低50%。联合治疗组36个月无病生存率达86%，单纯FOLFOX6化疗组为76%。阿替利珠单抗可特异性结合肿瘤细胞及肿瘤浸润免疫细胞表面的PD-L1蛋白，阻断其与PD-1、B7.1受体的相互作用。通过抑制PD-L1通路，阿替利珠单抗能够重新激活效应T细胞抗肿瘤免疫。
罗氏：6月12日，罗氏宣布，VENTANA PTEN（SP218）伴随诊断试剂盒成为首款获美国FDA批准、用于检测前列腺癌肿瘤组织PTEN蛋白缺失的免疫组织化学伴随诊断试剂。经该试剂盒检出PTEN蛋白缺失的患者，可具备使用阿斯利康靶向药TRUQAP（capivasertib）开展治疗的适用资格。TRUQAP用于PTEN缺陷型转移性雄激素通路未接受过调控治疗/雄激素通路敏感型前列腺癌（既往称转移性激素敏感性前列腺癌）患者。口服、ATP竞争性、高选择性泛AKT激酶抑制剂，可同时强效抑制AKT1、AKT2、AKT3全部3种亚型。
辉瑞：6月8日，辉瑞宣布，美国FDA批准HYMPAVZI（marstacimab）扩大适应症，用于12岁及以上伴抑制物的A型或B型血友病患者，以及6~11岁无论是否伴抑制物的儿童血友病患者。目前该药物在美国获批完整适应症为：用于6周岁及以上成人及儿童A型血友病（先天性凝血因子Ⅷ缺乏症）、B型血友病（先天性凝血因子Ⅸ缺乏症）患者（无论是否产生凝血因子抑制物）的常规预防治疗，以预防或减少出血发作频次。凝血因子替代疗法会诱发抑制物产生，大幅压缩血友病患者的治疗选择，同时难以有效控制出血。Ⅲ期BASIS临床试验数据证实，相较于按需静脉输注旁路制剂，HYMPAVZI疗效更优：经治疗年化出血率（ABR）相对降幅高达93%。Ⅲ期BASIS KIDS儿童试验中期数据结果，6~17周岁无抑制物患儿：HYMPAVZI组经治疗年化出血率均值1.8，历史常规预防治疗模型对照组均值3.6。6~17周岁伴抑制物患儿：HYMPAVZI组经治疗年化出血率均值1.4；历史按需治疗模型对照组均值18.9。既往按需治疗的伴抑制物6~11岁患儿、既往接受常规预防治疗的无抑制物6~11岁患儿，模型校正后经治疗年化出血率均值分别为1.3、1.4，中位年化出血率均为1.0。HYMPAVZI由辉瑞自研，作用机制与凝血因子Ⅷ、Ⅸ替代疗法存在本质差异。该药物不补充缺失或不足的凝血因子，而是靶向人体内天然抗凝物质组织因子途径抑制物（TFPI），阻断凝血启动环节。药物结合TFPI的库尼茨2结构域，重建机体出血与凝血的动态平衡，实现长效防出血。
阿斯利康：6月12日，阿斯利康宣布，TRUQAP（capivasertib）联合阿比特龙+泼尼松方案在美国获批，用于靶向治疗成人PTEN缺失型转移性雄激素通路未经调控/雄激素通路敏感型前列腺癌的药物，即转移性激素敏感性前列腺癌。批准依据Ⅲ期CAPItello-281临床试验阳性结果，数据已于2025年欧洲肿瘤内科学会年会公布，并同步发表于《肿瘤学年鉴》。主要分析结果显示：相较于阿比特龙+雄激素剥夺治疗联合安慰剂组，TRUQAP联合阿比特龙+雄激素剥夺治疗方案可使患者影像学疾病进展或死亡风险统计学显著降低19%，中位影像学无进展生存期延长7.5个月，具备明确临床获益。TRUQAP联合组中位影像学无进展生存期为33.2个月，对照组为25.7个月。主要分析开展时总生存期数据尚未成熟，但数值上TRUQAP联合组更具优势；TRUQAP是强效ATP竞争性AKT抑制剂，可同时靶向抑制AKT1、AKT2、AKT3全部三种亚型。由阿斯利康联合Astex Therapeutics共同研发。
拜耳：6月10日，拜耳宣布，欧洲药品管理局已正式受理并启动审评其口服凝血因子XIa（FXIa）抑制剂asundexian的上市许可申请，适应症为：用于成人非心源性缺血性卒中或高危短暂性脑缺血发作后缺血性卒中的二级预防。申请依托OCEANIC-STROKE研究阳性关键数据：在联用抗血小板治疗的前提下，相较于安慰剂，50mg asundexian可使患者缺血性卒中复发风险显著降低26%，且未增加ISTH标准大出血风险。
礼来：6月9日，礼来宣布，美国FDA批准EBGLYSS（lebrikizumab）全新给药方案：体重≥40千克（88磅）、12周岁及以上中重度特应性皮炎成人及青少年患者，采用单针皮下注射制剂（250毫克/2毫升），每8周一次维持给药。此前该药物已获批每月一次维持给药方案，长期临床数据证实其可实现持续病情控制。审批基于Ⅲ期ADjoin长期临床试验延展期每8周给药临床结果支持；该延展试验为期32周，对比评估EBGLYSS每4周、每8周两种维持给药方案。礼来拥有EBGLYSS在美国及欧洲以外全球其余地区的独家开发与商业化权益；Almirall获得该药物欧洲地区皮肤科适应症（含特应性皮炎）的开发及商业化授权。EBGLYSS是单抗药物，可高亲和力特异性结合并中和白介素-13（IL-13），解离速率缓慢。该抗体结合位点与IL-13Rα1/IL-4Rα异二聚体中的IL-4Rα亚基结合区域重叠，阻断受体复合物形成，抑制IL-13下游信号通路。IL-13是驱动特应性皮炎发病的核心细胞因子，诱发皮肤2型炎症级联反应。
赛诺菲：6月8日，赛诺菲宣布，欧盟委员会已批准Sarclisa（isatuximab，伊沙妥昔单抗）皮下注射剂型联合标准治疗方案，用于原静脉输注剂型在欧盟获批的全部多发性骨髓瘤适应症。本品是欧盟首款可采用穿戴式输注装置给药、同时支持手动皮下注射的抗肿瘤药物。批准基于Ⅲ期IRAKLIA研究数据，证实皮下剂型非劣效于静脉剂型。IRAKLIAⅢ期研究：穿戴式装置皮下给药组70%患者对注射流程表示满意或非常满意，静脉输注组为53.4%；IZALCOⅡ期研究：受试者先后体验两种皮下给药方式后，74.5%选择穿戴式装置给药，仅17%倾向手动注射，8.5%无偏好。伊沙妥昔单抗皮下制剂配套使用Enable Injections公司研发的CirCLIQ穿戴式输注装置，该设备依托enFuse技术平台打造，一键即可完成皮下给药，CirCLIQ配备回缩式隐藏针头，相较于常规大容量皮下注射针头更短、更细。采用穿戴式装置皮下伊沙妥昔单抗联合Pd（泊马度胺、地塞米松）方案，客观缓解率达71.1%；静脉伊沙妥昔单抗联合Pd方案组为70.5%，达到预设非劣效标准。伊沙妥昔单抗是靶向CD38的人源化IgG1单克隆抗体，靶点CD38，高度稳定表达于多发性骨髓瘤恶性浆细胞膜表面，正常造血细胞低表达，具备高度肿瘤选择性。
赛诺菲：6月13日，赛诺菲宣布，美国FDA加速批准了Tzield（teplizumab），用于延缓8~17岁新近确诊3期1型糖尿病患儿自身内源性胰岛素分泌能力衰退。无法作为非自身免疫性糖代谢异常疾病的修正疗法。批准依据Ⅲ期PROTECT研究数据：试验终点为β细胞功能评价，相较安慰剂组，可显著减缓平均C肽水平下降速度。Tzield是靶向CD3的单克隆抗体，是全球首款针对自身免疫性1型糖尿病的疾病修正疗法。
诺和诺德：6月11日，诺和诺德宣布，每日一次新型体重管理片剂Wegovy（司美格鲁肽片剂）已在英国获批上市，可配合低热量饮食与增加运动联用，为成年患者提供了可替代注射制剂的口服GLP‑1治疗选择。Wegovy为口服胰高血糖素样肽‑1（GLP‑1）受体激动剂，获批适应症为体重管理。获批依据OASIS 4Ⅲ期临床试验数据。在生活方式干预基础上，肥胖受试者每日服用25mg司美格鲁肽片剂，治疗64周后体重平均下降13.6%；安慰剂组仅下降2.4%。
武田制药：6月9日，武田制药宣布，美国FDA已受理其维得利珠单抗静脉注射剂型（ENTYVIO，vedolizumab）的补充生物制品许可申请，拟用于2岁及以上中重度活动性溃疡性结肠炎和克罗恩病儿科患者的治疗。武田制药已同步向欧洲药品管理局递交静脉输注Entyvio的上市许可申请，申请基于针对溃疡性结肠炎的KEPLER研究，以及仍在推进中的克罗恩病WEBB研究。KEPLER研究主要终点为经维得利珠单抗静脉诱导治疗达到临床应答的患儿在第54周实现临床缓解；WEBB研究设置共同主要终点，即第54周临床缓解与内镜下应答双重指标。Entyvio是生物制剂，可特异性结合整合素α4β7，阻断其与主要表达于肠道内皮细胞的MAdCAM-1相结合。
中外制药：6月12日，中外制药宣布，已向日本监管部门递交抗癌药物、人源化抗PD‑L1单克隆抗体泰圣奇（阿替利珠单抗注射液，1200毫克，Tecentriq，atezolizumab）的新增适应症上市申请，拟用于局部晚期食管癌根治性放化疗后的维持治疗。申请依托全球Ⅲ期临床试验（SKYSCRAPER‑07/YO42137）研究数据，泰圣奇单药组在主要终点总生存期、次要终点研究者评估无进展生存期上持续展现临床获益。
欧加隆：6月10日，欧加隆宣布，美国FDA已批准TOFIDENCE（tocilizumab）注射液静脉输注剂型的补充生物制品许可申请。是雅美罗（ACTEMRA）的生物类似药，本次获批拓展两项新适应症：用于2岁及以上CAR T细胞疗法引发的重度或危及生命的细胞因子释放综合征；住院成人及儿童新冠病毒肺炎患者，该类患者正在接受全身糖皮质激素治疗，且需要氧疗、无创或有创机械通气或体外膜肺氧合（ECMO）支持。欧加隆于2025年获得TOFIDENCE在美国的注册申报及商业化权益；该产品研发方百奥泰生物制药股份有限公司保留该产品美国市场的生产权益。TOFIDENCE为白介素-6（IL-6）受体拮抗剂。
合作授权方面：
罗氏：6月8日，罗氏宣布，与Nurix Therapeutics, Inc.签署独家授权及合作协议。双方将联合开发、共同商业化推进Nurix在研布鲁顿酪氨酸激酶（BTK）降解剂bexobrutideg（NX-5948）。临床开发计划覆盖B细胞恶性肿瘤、免疫学疾病及神经疾病三大领域。计划于2026年夏季启动针对慢性淋巴细胞白血病二线治疗的Ⅲ期临床试验。Nurix将获得7亿美元首付款，同时有资格收取开发、注册及销售里程碑款项，交易潜在总金额最高可达23亿美元。双方按比例分摊研发成本：Nurix承担40%，罗氏承担60%。美国地区商业化产生的损益由两家公司平分，在美国所有适应症的商业化工作由双方共同开展。美国境外市场由罗氏全权负责商业化推广，Nurix可获得中低十位数至高十位数区间的分层特许权费。Bexobrutideg可利用人体自身蛋白降解系统，选择性降解细胞内BTK蛋白，同时消除其激酶活性与支架双重功能，有望克服现有疗法继发耐药突变。
收并购方面：
强生：6月8日，强生宣布，已签署最终收购协议，将以10亿美元现金收购Firefly Bio, Inc.。这家生物科技企业自主研发了专有Firelink降解剂抗体偶联物（DAC）技术平台。针对KRAS突变驱动型肿瘤的Firelink DAC平台。可向肿瘤细胞精准递送高选择性蛋白降解剂，同时不损伤健康细胞。
葛兰素史克：6月9日，葛兰素史克宣布，已签署收购协议，斥资106亿美元收购总部位于波士顿的临床阶段生物制药企业Nuvalent, Inc.，专注研发精准靶向抗肿瘤疗法。Zidesamtinib（NVL-520）与neladalkib（NVL-655）是两款处于临床后期的新一代高选择性ROS1、ALK抑制剂，拟用于非小细胞肺癌治疗。两款药物均已获得美国FDA突破性疗法认定及孤儿药资格认定，目前正在审评阶段，FDA预定决议日期分别为2026年9月18日（zidesamtinib）、2026年11月27日（neladalkib）。预计2026年实现商业化上市。第三款资产NVL-330是HER2抑制剂，当前处于Ⅰ期临床阶段，适应症为HER2突变非小细胞肺癌。葛兰素史克将发起要约收购，以每股124美元现金对价收购全部普通股。交易股权总价值约106亿美元。扣除标的账面现金后，实际净投入约94亿美元。
梯瓦：6月10日，梯瓦制药宣布，已完成对Emalex Biosciences的收购。将ecopipam纳入梯瓦后期临床管线，ecopipam Ⅲ期临床试验数据近期已刊发于《美国医学会杂志・神经病学分册》（JAMA Neurology），预计将于2026年下半年向美国FDA递交新药上市申请。Ecopipam是在研候选药物，作用机制为阻断多巴胺D1受体信号传导。D1受体超敏反应被认为参与介导了抽动秽语综合征伴随的重复、强迫性行为。美国FDA已授予ecopipam用于儿童抽动秽语综合征治疗的孤儿药资格与快速通道资格。梯瓦支付7亿美元，Emalex股东将根据未来商业里程碑以及依全球净销售额计算的ecopipam的专利使用费获得最高2亿美元的额外收益。
临床进展方面：
强生：6月11日，强生公布Ⅱ/Ⅲ期ENERGY研究完整核心数据：相较于安慰剂组，30mg/kg剂量组IMAAVY（nipocalimab）治疗温抗体型自身免疫性溶血性贫血，可实现具有统计学意义的持续性血红蛋白应答，且起效迅速。这项随机、安慰剂对照临床试验显示，给药24周时，达到持续性血红蛋白达标标准的患者数量约为安慰剂组的3倍。最早在第1周即可观测到血红蛋白平均升高至少1g/dL。研究数据将在2026年欧洲血液学协会年会上发布。本研究以持续性血红蛋白改善为主要终点，对比IMAAVY与安慰剂的疗效，30mg/kg给药组在第1周血红蛋白平均升高1g/dL，而安慰剂组血红蛋白无变化。温抗体型自身免疫性溶血性贫血的治疗目标是维持血红蛋白≥10g/dL，且较基线上升≥2g/dL，至第24周时，近三分之二受试者同时达成两项治疗目标。本研究两项关键次要终点同样获得阳性结果：患者疲乏症状改善、激素用量减少。早在第2周即可观察到患者报告疲乏评分改善，且该获益在24周完整治疗周期内持续维持。IMAAVY为免疫选择性治疗药物，可高亲和力结合并阻断新生儿Fc受体（FcRn），降低循环中致病IgG自身抗体水平，同时保留机体关键免疫功能。
强生：6月13日，强生公布Ⅲ期临床试验MonumenTAL-3研究关键数据。结果显示：靶向GPRC5D的双特异性抗体TALVEY(talquetamab）联合达雷妥尤单抗透明质酸酶注射液（DARZALEX FASPRO，daratumumab+透明质酸酶），联合或不联合泊马度胺方案，用于复发/难治性多发性骨髓瘤患者，相较标准DPd方案（达雷妥尤单抗透明质酸酶注射液+泊马度胺+地塞米松），可将患者疾病进展或死亡风险最高降低72%，死亡风险临床意义降幅最高达53%。随访至24个月时，联合方案无进展生存期率最高可达81.3%，而标准治疗组仅为51.2%；总生存期率最高为89.2%，标准治疗组为79.1%。数据已于2026年欧洲血液学协会年会公布，并同步刊发于《新英格兰医学杂志》。TALVEY+达雷妥尤单抗透明质酸酶组、TALVEY+达雷妥尤单抗透明质酸酶+泊马度胺组积标准方案组，客观缓解率分别为：88.2%、88.5%、77.6%；≥完全缓解率分别为：71.1%、68.9%、34.5%；MRD阴性≥完全缓解率分别为：52.3%、46.3%、15.9%。TALVEY是T细胞衔接型双特异性抗体：一端结合T细胞表面CD3受体，另一端结合全新骨髓瘤靶点G蛋白偶联受体C族5型D受体（GPRC5D）。达雷妥尤单抗是抗CD38靶向抗体。2012年8月，杨森生物与Genmab公司签署全球独家合作协议，杨森获得达雷妥尤单抗全球开发、生产及商业化独家授权。
艾伯维：6月8日，艾伯维宣布，将在2026年欧洲血液学协会年会上公布多项全新研究数据，epcoritamab的最新数据包括：epocoritamab联合来那度胺+利妥昔单抗方案用于复发/难治性滤泡性淋巴瘤的疗效分析方面，Ⅲ期EPCORE FL-1试验纳入243例患者，固定疗程epcoritamab联合利妥昔单抗+来那度胺方案，对比利妥昔单抗+来那度胺方案，按滤泡性淋巴瘤国际预后指数（FLIPI）分层：试验组客观缓解率数值上均高于对照组；FLIPI 0~2分：96.5%对比84.8%；FLIPI 3~5 分：93.0%对比72.6%。一线治疗后2年内疾病进展患者亚组也呈现相同获益趋势。年龄分层：≥65岁人群，试验组客观缓解率、完全缓解率分别为94.3%、80.7%，对照组对应为80.2%、44.3%；＜65岁人群，两组客观缓解率分别为95.5%、78.4%，完全缓解率分别为83.9%、54.0%。依据NHL-5合并症指数分层：低评分亚组无进展生存期风险比0.27；中高评分亚组为0.14。epcoritamab单药用于经系统治疗后的复发/难治性大B细胞淋巴瘤疗效方面，EPCORE DLBCL-1试验为随机Ⅲ期研究，对照组为研究者自选免疫化疗方案：利妥昔单抗+吉西他滨+奥沙利铂，或苯达莫司汀+利妥昔单抗。主要终点：试验组无进展生存期相较对照组显著改善；24个月无进展生存率30%相比13%。总生存期未达到统计学显著差异。缓解指标：试验组完全缓解率38%，对照组26%；中位缓解持续时间37个月相比6个月；中位完全缓解持续时间为未达到相比11个月；至下次治疗间隔为7个月相比4个月。Epcoritamab是人源化IgG1型CD3×CD20 T细胞衔接型双特异性抗体。
艾伯维：6月12日，艾伯维于2026年欧洲血液学协会年会上，公布针对初治慢性淋巴细胞白血病的Ⅲ期CLL14研究最终结果，头对头对比venetoclax联合obinutuzumab、苯丁酸氮芥联合obinutuzumab两种方案。结果显示，venetoclax联合方案可显著延长患者无进展生存期（中位无进展生存期分别位6.4年相比3.2年），9.2年随访分析进一步证实联合方案具备长期停药后的持续疗效与可靠安全性，其中位至下次治疗时间达7.6年。VENCLYXTO（venetoclax，维奈克拉）可选择性结合并抑制B细胞淋巴瘤-2（BCL-2）蛋白。在部分血液肿瘤中，BCL-2蛋白会阻断肿瘤细胞发生生理性程序性死亡。维奈克拉由艾伯维与罗氏联合研发；在美国市场，由艾伯维联合罗氏旗下基因泰克共同商业化推广；美国以外地区由艾伯维单独负责商业化。奥妥珠单抗（obinutuzumab，佳罗华，Gazyva）是糖基工程化人源化Ⅱ型抗CD20 IgG1单克隆抗体，由罗氏生产。
葛兰素史克：6月12日，葛兰素史克宣布，JAK抑制剂momelotinib，获美国FDA与欧洲药品管理局授予孤儿药资格认定，用于治疗VEXAS综合征（Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic）。VEXAS综合征属于克隆性髓系疾病，兼具风湿免疫及血液系统临床表现；momelotinib（Ojjaara/Omjjara）可同时抑制三条关键信号通路：JAK1、JAK2以及Ⅰ型激活素A受体（ACVR1）。抑制JAK1、JAK2通路可改善患者全身症状、缩小肿大脾脏；抑制ACVR1能够降低循环铁调素水平，进而改善贫血相关症状。
阿斯利康：6月8日，阿斯利康宣布，口服小分子胰高血糖素样肽-1受体激动剂（GLP‑1 RA）elecoglipronⅡb期VISTA、SOLSTICE两项临床试验取得阳性关键结果，研究数据在美国糖尿病协会2026年科学年会公布，并同步刊发于《柳叶刀》杂志；VISTA试验中，入组肥胖或超重且合并至少一项合并症的成人受试者，75mg剂量组达到预设双重主要终点：治疗26周时，受试者平均体重较基线临床及统计学显著下降10.5%，安慰剂组仅下降0.6%。减重效应未出现平台期，给药至36周时75mg剂量组体重降幅进一步扩大至11.8%，安慰剂组仅下降0.3%。试验另一项共同主要终点（26周体重降幅≥5%受试者占比）同样达标：75mg剂量组最高可达88.8%的受试者实现该减重目标。除此之外，多项探索性分析显示可显著改善多项心代谢风险指标，包括血压降低、全身炎症标志物C反应蛋白水平下降等。SOLSTICE试验入组2型糖尿病成人患者，试验主要终点结果显示：治疗26周时，75mg组糖化血红蛋白（HbA1c）较基线平均下降1.9%，具备临床及统计学双重显著获益；安慰剂组仅下降0.2%。绝大多数受试者在26周时达到指南推荐血糖控制目标：90%受试者HbA1c降至7%以下，85%受试者HbA1c≤6.5%。同时该剂量组受试者平均体重下降7.7%，安慰剂组仅下降1.7%，减重获益明确。elecoglipron是每日口服一次的小分子GLP‑1受体激动剂，可模拟人体内天然GLP‑1激素的作用。作用于肠道及下丘脑内的受体，通过脑‑肠轴通路调控进食量与机体代谢功能。
诺华：6月11日，诺华宣布，delpacibart braxlosiran（del-brax）的Ⅰ/Ⅱ期FORTITUDE研究生物标志物队列达成主要终点及关键次要终点：受试者体内KHDC1L（cDUX）与肌酸激酶生物标志物水平均出现下降，证实该药物强效实现靶点结合，同时患者肌肉损伤得到缓解。本研究入组面肩肱型肌营养不良症患者。del-brax是在研抗体寡核苷酸偶联药物（AOC），属于全新RNA治疗药物类别。疾病发病根源为DUX4基因异常表达，del-brax精准针对这一病因设计。兼具单克隆抗体的组织靶向特异性与寡核苷酸的精准作用优势，可将小干扰RNA（siRNA）定向递送至既往难以靶向作用的患者肌细胞内，抑制DUX4基因表达。del-brax源自于2026年2月诺华对Avidity Biosciences的收购。
诺华：6月12日，诺华宣布，在欧洲过敏与临床免疫学会年会上公布RemIND临床试验研究数据：Rhapsido（remibrutinib）在三种最常见的慢性诱导性荨麻疹亚型中均达成主要研究终点。结果显示，治疗第12周时完全缓解率显著提升；其中两种亚型最早在第2周即可观察到治疗应答。对于三种亚型，第12周完全反映率，针对症状性皮肤划痕症，Rhapsido组为29.3%，安慰剂组为14.0%。针对寒冷性荨麻疹为56.3%相比14.6%，针对胆碱能性荨麻疹为29.3%相比15.8%。Rhapsido是高选择性口服BTK抑制剂，可阻断BTK信号通路；该通路参与组胺释放，而组胺是诱发风团、水肿等荨麻疹症状的核心致病介质。
礼来：6月8日，礼来公布ACHIEVE项目三项Ⅲ期临床试验完整详细数据，该系列试验评估小分子口服GLP‑1制剂Foundayo（orforglipron）用于成人2型糖尿病治疗，本品服用无需忌口、也无需饮水限制。里程碑式头对头对照ACHIEVE‑3试验显示，在主要终点及全部关键次要终点上疗效均优于口服司美格鲁肽；ACHIEVE‑2、ACHIEVE‑5试验也全部达成主要终点与关键次要终点：相较于联合甘精胰岛素基础上加用达格列净、安慰剂，Foundayo分别实现更显著的糖化血红蛋白降幅与减重效果。上述三项研究数据于第86届美国糖尿病协会科学年会公布；其中ACHIEVE‑3试验此前已发表于《柳叶刀》，ACHIEVE‑2、ACHIEVE‑5则分别刊发在《柳叶刀》与《美国医学会杂志（JAMA）》。ACHIEVE‑3用于2型糖尿病的Ⅲ期头对头对照试验：9mg、17.2mg剂量Foundayo疗效全面优于7mg、14mg剂量口服司美格鲁肽。治疗52周时：糖化血红蛋白（A1C）降幅：Foundayo 9mg组平均下降1.9%、17.2mg组下降2.2%；口服司美格鲁肽7mg组下降1.1%、14mg组下降1.4%；最高剂量组相对降幅提升57.1%。血糖正常达标率（A1C＜5.7%）：Foundayo最高剂量组达标患者占比37.1%，口服司美格鲁肽最高剂量组仅12.5%。减重效果：Foundayo 9mg组平均减重14.6磅（体重降幅6.7%）、17.2mg组平均减重19.7磅（降幅9.2%）；口服司美格鲁肽7mg组减重7.9磅（降幅3.7%）、14mg组减重11.0磅（降幅5.3%）；最高剂量组相对减重幅度高出73.6%。ACHIEVE‑2试验结果，治疗40周时，两组受试者基线平均糖化血红蛋白（A1C）为8.1%。Foundayo降糖疗效更优，糖化血红蛋白最大平均降幅达1.7%，而达格列净组仅下降0.8%。Foundayo最高剂量组有68.6%的患者糖化血红蛋白降至≤6.5%（强化血糖控制目标），达格列净组该比例仅为21.6%。减重数据：Foundayo 2.5mg、9mg、17.2mg剂量组平均减重分别为7.1磅（体重降幅3.5%）、12.8磅（6.3%）、15.0磅（7.3%）；达格列净组平均减重6.0 磅（3.0%）。ACHIEVE‑5试验结果，在滴定剂量甘精胰岛素基础上联用Foundayo，疗效显著优于联用安慰剂组。受试者基线平均糖化血红蛋白为8.5%，治疗40周后，Foundayo组糖化血红蛋白最大平均降幅达2.1%，安慰剂组仅下降0.8%。Foundayo 9mg剂量组69.1%的患者糖化血红蛋白控制至≤6.5%，安慰剂组仅11.1%。减重数据：Foundayo 2.5mg、9mg、17.2mg剂量组平均减重依次为4.9磅（2.7%）、11.0磅（5.8%）、11.5磅（6.1%）；安慰剂组体重反而平均增加1.1磅（0.6%）。三项临床试验统一分析显示，Foundayo可多项关键心血管危险因素较基线出现具有临床意义的改善，涵盖非高密度脂蛋白胆固醇、高密度脂蛋白胆固醇、极低密度脂蛋白胆固醇、总胆固醇、收缩压以及甘油三酯。Foundayo分子由日本中外制药研发，2018年授权给礼来。
礼来：6月13日，礼来公布Ⅰ期AJX-101研究最新数据：其在研Ⅱ型JAK2抑制剂AJ1-11095，在经Ⅰ型JAK2抑制剂治疗失败的骨髓纤维化患者中展现出安全性可控、临床活性可观的试验结果。这款Ⅱ型JAK2抑制剂可选择性结合JAK2激酶的Ⅱ型构象。礼来近期完成对Ajax Therapeutics Inc.的收购获得该管线。数据将在2026年欧洲血液学协会年会上发布。AJ1-11095在脾脏体积缩小、症状改善两项常规疗效终点上均观察到治疗应答。最佳疗效中70%的患者实现脾脏体积缩小≥35%（SVR35）；治疗第12周时，70%患者症状负荷改善≥50%（TSS50）。此外，23例受试者中有21例出现驱动突变等位基因频率（VAF）下降。17例完成24周治疗的患者中，59%突变等位基因频率降幅≥20%，35%降幅≥50%，涉及JAK2、MPL、CALR 1型及2型各类突变。现有Ⅰ型JAK2抑制剂极少能实现突变等位基因频率持续下降这一效果。AJ1-11095靶向结合JAK2非活化构象，可更彻底阻断驱动骨髓纤维化的异常信号通路。临床前骨髓纤维化模型中，AJ1-11095活性优于芦可替尼（Ruxolitinib，Jakafi）。
赛诺菲：6月10日，赛诺菲宣布，针对经标准治疗无效的慢性炎症性脱髓鞘性多发性神经根神经病患者开展的针对riliprubart的MOBILIZEⅢ期临床试验将终止入组与试验开展。独立数据监查委员会开展中期分析后判定，该试验难以达到预设充分疗效终点；本次中期分析未发现与riliprubart相关的安全性风险信号。riliprubart其余正在进行中的临床试验，包括针对接受静脉注射免疫球蛋白治疗的神经根神经病患者开展的VITALIZEⅢ期试验，公司将另行评估后续推进方案。riliprubart为IgG4型人源化单克隆抗体，可选择性抑制固有免疫系统经典补体通路中的活化C1s分子。通过阻断C1s活性，该候选药物有望抑制疾病发病过程中引发神经脱髓鞘及轴索损伤的核心炎症机制。
诺和诺德：6月7日，诺和诺德宣布，REIMAGINE 1–3三项Ⅲ期临床试验完整结果，证实CagriSema复方制剂可显著降低2型糖尿病成人患者的糖化血红蛋白（HbA1c）并减轻体重。REIMAGINE系列每项试验均达成主要终点，糖化血红蛋白降幅具备统计学显著性；同时达到体重下降的确证性次要终点。全套数据于美国糖尿病协会2026年科学年会发布；REIMAGINE 1、2试验结果同步刊发于《柳叶刀・糖尿病与内分泌学》，REIMAGINE 3试验结果刊登在《柳叶刀》主刊。REIMAGINE临床项目评估CagriSema用于2型糖尿病成人患者。REIMAGINE 1试验中，糖化血红蛋白基线水平7.8%，体重基线水平101.3kg，40周CargiSema 2.4mg/2.4mg组，糖化血红蛋白下降1.8%，体重下降13.8%，1mg/1mg组糖化血红蛋白下降1.5%，体重下降11.8%，安慰剂组糖化血红蛋白下降0.1%，体重下降1.4%。REIMAGINE 2试验中，糖化血红蛋白基线水平8.2%，体重基线100.9kg，68周CargiSema 2.4mg/2.4mg组糖化血红蛋白下降1.91%，体重下降14.2%，司美格鲁肽2.4mg组，糖化血红蛋白下降1.75%，体重下降10.2%。Cagrilintide 1mg组糖化血红蛋白下降0.80%，体重下降8.4%。CargiSema 1mg/1mg组糖化血红蛋白下降1.82%，体重下降12%，司美格鲁肽1mg组糖化血红蛋白下降1.54%，体重下降7.5%。安慰剂组糖化血红蛋白增长0.09%，体重下降1.5%。REIMAGINE 3试验中，基线糖化血红蛋白8.8%，基线体重88kg。40周CargiSema 2.4mg/2.4mg组糖化血红蛋白下降2.33%，体重下降12%。CargiSema 1mg/1mg组糖化血红蛋白下降2.10%，体重下降10.4%，安慰剂组糖化血红蛋白下降0.66%，体重增长1.1%。CargiSema是固定剂量复方制剂，由长效胰淀素类似物cagrilintide与GLP‑1受体激动剂司美格鲁肽组成。
吉利德：6月8日，默沙东与吉利德共同宣布，终止Ⅲ期KEYNOTE‑D46/EVOKE‑03临床试验。旨在评估吉利德的Trodelvy（sacituzumab govitecan）联合默沙东抗PD‑1疗法可瑞达（帕博利珠单抗，Keytruda，pembrolizumab），对比帕博利珠单抗单药一线治疗肿瘤PD‑L1表达阳性（肿瘤细胞阳性比例评分TPS≥50%）的转移性非小细胞肺癌初治患者。该终止决定基于独立外部数据监查委员会对预设无进展生存期最终分析、总生存期中期分析数据审阅后给出的建议。研究观察到联合组无进展生存期存在数值上的优势，但未达到统计学显著性；按预设方案开展最终分析时，总生存期取得统计学阳性结果的可能性极低。Trodelvy是靶向Trop‑2的抗体偶联药物，采用自研可裂解连接子偶联拓扑异构酶Ⅰ抑制剂SN‑38载荷。帕博利珠单抗是人源化IgG4型抗PD‑1单克隆抗体，特异性结合T淋巴细胞表面的程序性死亡受体1（PD‑1）。
吉利德：6月8日，吉利德与默沙东联合宣布，在两项Ⅲ期ISLEND‑1、ISLEND‑2临床试验中，在研每周一次单片口服艾滋病治疗复方islatravir/lenacapavir (ISL/LEN)均达到第48周主要疗效终点。ISLEND系列试验评估2mg islatravir+300mg lenacapavir方案，用于病毒学抑制的HIV感染者换药治疗：ISLEND‑1受试者原服用必妥维（BIKTARVY，比克替拉韦50mg/恩曲他滨200mg/丙酚替诺福韦25mg）；ISLEND‑2受试者沿用既往标准抗逆转录病毒方案。ISLEND‑1与ISLEND‑2的主要疗效终点，均为依据美国FDA快照判定标准，第48周时HIV‑1 RNA病毒载量≥50拷贝/毫升的受试者占比。双盲设计的ISLEND‑1试验证实，每周单片ISL/LEN方案相较于必妥维达到统计学非劣效标准；开放标签的ISLEND‑2试验证实，ISL/LEN相较于每日口服标准抗逆转录病毒治疗方案同样实现统计学非劣效。Lenacapavir为HIV衣壳抑制剂，作用机制分多阶段调控，可在HIV生命周期多个节点产生抑制作用。Islatravir（MK‑8591）是默沙东开发的强效新一代核苷类似物，通过多重机制阻断HIV‑1复制：抑制逆转录酶移位实现即时链终止，同时诱导病毒DNA构象改变引发延迟链终止。
勃林格殷格翰：6月7日，勃林格殷格翰公布胰高血糖素/GLP‑1双受体激动剂survodutide（BI 4569066）两项全球Ⅲ期临床试验（SYNCHRONIZE‑1、SYNCHRONIZE‑MASLD）阳性结果。分别针对两类受试人群。SYNCHRONIZE‑1入组不合并2型糖尿病的肥胖/超重成人受试者；SYNCHRONIZE‑MASLD入组合并炎症和（或）纤维化的代谢功能障碍相关脂肪性肝病超重/肥胖成人受试者。两项研究完整数据于本届美国糖尿病协会2026年科学年会正式发布，且分别同步刊发于《新英格兰医学杂志》与《自然・医学》。SYNCHRONIZE‑1研究中，为期76周，4月先期披露的顶线数据显示，研究均达成预设主要终点。受试者最高平均体重降幅可达16.6%，安慰剂组仅下降3.2%，组间差异具备统计学显著性。一项亚组分析纳入基线及研究终点均完成磁共振检测的用药受试者，内脏脂肪相对降幅最高达34.0%。最高剂量组受试者总体组织重量变化中，瘦体重占比不超过10.8%，证实减重核心来源于脂肪组织减少。受试者肝脏脂肪最高相对降幅可达63.1%，再次印证该药物对代谢健康的正向调控潜力。SYNCHRONIZE‑MASLD研究中，为期48周，试验入组合并炎症和（或）纤维化的脂肪性肝病超重/肥胖成人，受试者无论是否同时罹患2型糖尿病均被纳入研究。该研究均达成共同主要终点。治疗组最高84.2%受试者肝脏脂肪相对降幅≥30%，安慰剂组仅24.3%，差异统计学意义显著；另一项共同主要终点体重相对降幅方面，试验组最高减重12.2%，安慰剂组仅下降1.0%。次要终点详细数据显示，48周时，最高61.0%受试者实现肝脏脂肪含量正常化（肝脂肪占比＜5%），安慰剂组仅5.7%。多项评估肝功能生物标志物（如丙氨酸氨基转移酶ALT）的次要终点同样呈现积极趋势，提示肝脏炎症水平得到有效缓解。
武田制药：6月11日，武田制药公布Ⅲ期头对头研究关键顶线阳性结果，高选择性强效口服酪氨酸激酶2（TYK2）在研抑制剂zasocitinib（TAK‑279）对比氘可来昔替尼（Sotyktu，deucravacitinib），用于成人中重度斑块状银屑病治疗。LATITUDE Atlas临床试验显示，第16周银屑病面积与严重程度指数100（PASI 100）应答率这一主要终点上，zasocitinib疗效统计学显著优于Sotyktu。研究全部关键次要终点同样达到统计学优效标准，包括第16周PASI90应答率、医师静态总体评估（sPGA）达到0分（皮损完全清除）。第16周试验组超35%患者实现皮损完全清除（PASI 100），应答率是对照组的2.5倍以上；早在第8周两组疗效曲线就已拉开显著差距。Zasocitinib为新一代高选择性强效口服TYK2在研抑制剂，可24小时持续抑制白介素‑23（IL‑23）及多条驱动疾病进展的核心免疫通路。
梯瓦：6月8日，梯瓦制药公布全新研究数据，证实AUSTEDO与缓释片AUSTEDO XR（氘代丁苯那嗪）治疗可全面改善迟发性运动障碍各类症状。三项独立研究得出的新研究结果，已于美国Psych Congress Elevate上发布。IMPACT‑TD研究为真实世界登记研究，纳入起始使用Austedo或缓释片治疗的轻症患者。治疗3个月后，所有受试者异常不自主运动量表（AIMS）评分均出现下降，精神症状同时保持稳定；基线在日常生活能力、社会心理功能、言语沟通等维度存在明显功能受损的受试者，随着不自主运动症状减轻，上述各项功能指标均获得改善。RIM‑TD为3年的开放标签研究，事后分析显示，随治疗时间延长，产生治疗应答的患者占比逐步升高。15周内已有超50%患者AIMS评分改善；第15周之后又新增23%患者出现症状好转。该结果证实，坚持长期用药可进一步提升症状改善幅度。Austedo及缓释片是囊泡单胺转运蛋白2（VMAT2）抑制剂。
福泰制药：6月11日，福泰制药公布临床数据，证实CASGEVY（exagamglogene autotemcel）可给5岁及以上重度镰状细胞贫血病或输血依赖型β地中海贫血患者带来临床获益。数据在欧洲血液学协会大会公布，同步刊发于《新英格兰医学杂志》（NEJM）。重度镰状细胞贫血病Ⅲ期CLIMB‑151研究中，11名给药患儿均不再发生血管闭塞危象；具备充足随访数据的8名患儿达成主要终点，连续至少12个月无血管闭塞危象（VF12）。达到VF12终点的患儿，无危象持续中位时长为19.0个月。输血依赖型β地中海贫血Ⅲ期CLIMB‑141研究中，共计15名患儿完成给药；具备充足随访数据的8名患儿达成主要终点：连续至少12个月脱离输血，且加权平均血红蛋白水平≥9克/分升（TI12）。所有实现TI12终点的患儿在随访期间持续维持脱离输血状态，脱离输血中位时长为23.4个月。CASGEVY是非病毒载体、体外CRISPR/Cas9基因编辑细胞疗法，提取患者自身造血干祖细胞，精准在BCL11A基因红系特异性增强子区域制造双链断裂完成基因编辑；编辑后的细胞可使红细胞持续高表达胎儿血红蛋白（HbF）。胎儿血红蛋白是胎儿发育期天然存在的携氧血红蛋白，出生后会逐步转换为成人型血红蛋白。
财务业绩及股息发放方面：
雅培：6月12日，雅培宣布，普通股季度股息为每股0.63美元。将于2026年8月17日发放给2026年7月15日交易日收盘时登记在册的股东。
2026-06-12
·优在生物
导 语
分泌型TGF-β分子持续参与HIV潜伏储存库的稳态维持，是艾滋病功能性治愈难以落地的关键阻碍之一。现有“休克并杀灭”疗法普遍存在潜伏前病毒诱导效率偏低，病毒储存库缩减效果不达预期的现实难题。
多数潜伏逆转药物仅能实现病毒短暂激活，无法同步提升机体抗病毒免疫应答。TGF-β可调控T细胞代谢与分化进程，但靶向该通路能否在活体动物体内同步完成潜伏逆转与储库清除，此前仍缺少非人灵长类动物的完整实验证据。
2024年2月14日，美国西北大学Elena Martinelli团队在Nature Communications上发表了题为TGF-β blockade drives a transitional effector phenotype in T cells reversing SIV latency and decreasing SIV reservoirs in vivo的研究论文。
该研究选用Galunisertib开展非人灵长类动物实验，证实药物阻断TGF-β信号可推动T细胞向过渡效应表型转化，在无全身性炎症加剧的前提下激活潜伏SIV，显著降低多组织病毒储存库水平。靶向TGF-β通路可同步实现SIV潜伏逆转与储库衰减，打破单一潜伏激活药物无法增强特异性免疫的固有短板。相关数据为艾滋病临床治愈候选药物研发提供灵长类体内实证，助力优化现有ART联合治愈方案。
正 文
研究人员选取8只雌性印度恒河猴，构建条形码标记SIVmac239静脉感染模型，在感染第6周启动替诺福韦、恩曲他滨、多替拉韦三联ART抗病毒治疗。等待感染后35周，采用2周给药、2周停药的间歇方案，以20mg/kg每日两次口服Galunisertib，完整开展4轮给药周期，其中2只实验动物在第三、第四周期额外联用抗PD1抗体，其余6只单独使用受试药物。给药全程持续监测血浆病毒载量，借助64Cu标记探针的免疫PET/CT技术，动态追踪肠道、淋巴结等组织内病毒活化信号。实验数据显示，8只猕猴中有7只出现血浆病毒反弹，PET成像证实肠道与腋窝淋巴结出现特征性病毒信号升高，间歇式Galunisertib给药能够在ART抑制状态下诱导体内潜伏SIV重新活化。
为明确药物对病毒储存库与免疫细胞表型的调控规律，研究人员在给药前后分别采集外周血、肠道活检组织与淋巴结样本，一方面通过qPCR、IPDA完整定量细胞相关SIV总DNA与完整前病毒DNA，另一方面借助高维流式、批量转录组与单细胞RNA测序解析免疫细胞分子特征。检测结果表明，给药结束后受试动物肠道、淋巴结、外周血的细胞相关病毒DNA均出现统计学显著下降，PBMC内完整前病毒载量中位数下降0.53log，平行对照猴在同等ART干预下无储库衰减现象。测序数据佐证，TGF-β阻断会快速上调氧化磷酸化等代谢通路，CD4+T细胞内TCF1分子持续性下调，免疫细胞整体朝着过渡效应细胞表型发生分化，全血炎症因子浓度无异常升高。
研究人员依托SIV抗原肽ELISpot实验、病毒条形码测序与多指标相关性分析，进一步锚定表型变化、免疫应答与储库下降的内在关联。抗原刺激结果证实，Galunisertib处理后猕猴外周血淋巴细胞分泌IFN-γ与TNF-α的能力显著提升，SIV特异性细胞免疫被有效增强。病毒条形码测序发现，药物干预未改变病毒种群整体多样性，但各组织内部病毒条码分布比例发生明显偏移。相关性分析直接证实，CD4+T细胞TCF1下调幅度和肠道储库下降水平、SIV特异性干扰素分泌水平呈显著负相关，T细胞TCF1表达下调介导的效应表型转化是潜伏逆转与储库清除的核心驱动因素。
Galunisertib 增强 SIV 特异性免疫应答
总 结
总的来说，该研究依托非人灵长类SIV感染模型，验证临床在研药物Galunisertib通过阻断TGF-β受体信号，促使T、NK细胞发生代谢重编程并转变为过渡效应表型，在不诱发全身炎症不良反应的条件下完成潜伏病毒激活。多组织核酸定量、活体PET影像学、多组学测序和功能学实验共同佐证，TGF-β抑制剂可以同步实现潜伏逆转、抗病毒免疫增强与病毒储存库减量三重效果，弥补传统潜伏逆转剂仅能激活病毒却无法清除储库的短板。
该研究立足灵长类动物体内数据完善TGF-β调控HIV潜伏的分子机制，为艾滋病功能性治愈开辟全新联用思路，Galunisertib作为已进入肿瘤临床阶段的候选药物，具备快速转向HIV感染者临床试验的潜在可行性，也为后续新型潜伏逆转药物的靶点筛选提供可靠参考。
论文链接：
https://doi.org/10.1038/s41467-024-45555-x
END
内容为【优在生物】公众号原创，
转载请写明来源于【优在生物】
版权声明：本公众号标注原创的文章系作者个人学习心得，若有版权争议或标注差错，请联系我们。免责声明：本文内容仅供学术交流参考，不构成任何建议或承诺，优在生物不对因使用本文信息导致的任何后果负责。
2026-06-10
Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期
https://academic.oup.com/jac/issue
50th Anniversary Collection（50周年纪念合集）
Review（综述）
1
Artificial intelligence for improving decision-making in bacterial infection management: a narrative review
人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述
Anisia Talianu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470
Reviews（综述）
2
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America
耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现
Lillian Rose Giarratana and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340
3
Azithromycin resistance in non-typhoidal Salmonella: a review
非伤寒沙门氏菌对阿奇霉素的耐药性：综述
Zhe Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341
4
Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications
抗生素药效动力学：从最低抑菌浓度到高级指标及其应用
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374
5
Progress in the study of drug resistance mechanism of Bacillus cereus
蜡样芽孢杆菌耐药机制研究进展
Yuhang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399
6
The curious constraints on clofazimine
氯法齐明的奇特限制
Maple Goh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430
7
Antiplasmid systems: a novel strategy to combat antibiotic resistance
抗质粒系统：对抗抗生素耐药性的新策略
Mohd Asim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472
Systematic Review（系统综述）
8
Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes
欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述
Priya Shastri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407
9
Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method
用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述
Najla Alabdulkarim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446
Virtual Roundtable（虚拟圆桌会议）
10
Procalcitonin in the management of lower respiratory tract infection and sepsis
降钙素原在下呼吸道感染和败血症治疗中的应用
Ramy H Elshaboury and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298
Original Research（论著）
11
Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients
来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估
Chrisoula Tahtsidou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427
12
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435
13
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study
评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究
Nicolas Grégoire and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381
14
Real-life use of isavuconazole in Spanish children and adolescents
西班牙儿童和青少年中艾沙康唑的实际使用情况
Natalia Mendoza-Palomar and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394
15
No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis
基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号
Slobodan M Jankovic and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395
16
Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet
成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较
Nirjan Bhattarai and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396
17
Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies
CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究
Beibei Liang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398
18
Differences in prescription for impetigo and cellulitis across years in three European countries
三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异
Thomas Bettuzzi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400
19
β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit
重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度
Karolina Liljedahl Prytz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401
20
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较
Jelmer Raaijmakers and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402
21
Identification of antimicrobial resistance genes in Escherichia coli through network diffusion
通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因
Anis Mansouri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404
22
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease
依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估
Sanjay Singh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405
23
The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization
β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406
24
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction
解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系
Maria Montaner and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408
25
Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge
不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战
Ana C Almeida-Santos and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409
26
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study
在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果
Romain Palich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410
27
HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda
乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联
Anne Kapaata and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411
28
Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States
美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况
Sarah C J Jorgensen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412
29
Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies
奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究
Saskia E Mudde and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413
30
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023)
后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023）
Mekki F Bensaci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414
31
Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions
慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联
Gabriel P E Silveira and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416
32
Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis
博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析
Biao Tang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418
33
Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation)
基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释）
Yinzheng Zhong and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419
34
Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights
印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察
Shristi Verma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420
35
Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations
减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示
Yeleen Fromage and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421
36
Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates
基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性
Reham Mostafa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422
37
Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing
危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药
Sonya Tang Girdwood and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423
38
Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients
达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量
W Töpfer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424
39
Notable transmitted HIV drug resistance among people who inject drugs in Pakistan
巴基斯坦注射毒品人群中显著传播的HIV耐药性
Stephanie Melnychuk and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425
40
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium
协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性
Ahmed Ashrin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426
41
Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model
中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究
Panagiota-Christina Georgiou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431
42
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.
非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗
Clayton F Hausberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432
43
Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus
阿普拉霉素及其组合对脓肿分枝杆菌的增强活性
Yanqin Huang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433
44
Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene
印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制
Dipika Shaw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434
45
Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases
鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者
Delphine Girlich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436
46
Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli
blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征
Pengpeng Min and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437
47
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients
血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性
Thornthun Ueaphongsukkit and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439
48
In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales
头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性
Marion Dutkiewicz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440
49
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效
Kirby Patterson-Fahy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441
50
Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate
利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性
Ruonan Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442
51
Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?
重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？
Manon Launay and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443
52
National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析
Ernesto Martínez-Buitrago and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444
53
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens
基于模型的含固定剂量多替拉韦方案减量策略比较
Laura Dickinson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445
54
Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE)
住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究）
Pjotr P Temme and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447
55
Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes
奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究
Jose Valdes Ledesma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448
56
Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study
采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究
Sacha Kuil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451
57
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24
2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高
Josefine Ahlstrand and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452
58
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable
尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定
Cathia Soulie and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454
59
Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications
延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455
60
β-Lactam dosing in critically ill children: predictors for target non-attainment
危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素
Stef Schouwenburg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457
61
Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis
实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况
Barbara Alexander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461
62
In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes
携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462
63
Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input
预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联
María M Montero and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464
64
A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations
全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局
Efi Mantzourani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466
65
Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus
提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试
Henriëtte M Meliefste and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468
Research Letters（研究快报）
66
Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany
德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731
Henrike Krüger-Haker and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336
67
Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report
厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告
Monica Melchio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347
68
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加
Jose F Camargo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348
69
Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring
达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用
Ambra Barco and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365
70
Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report
血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告
Kohei Hasegawa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373
71
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390
72
Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy
产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播
Gloria D’Achille and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397
73
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据
Tommaso Clemente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415
74
Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker
猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况
Gi Yong Lee and Soo-Jin Yang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428
75
Importance of reviewing the package insert from gradient strip manufacturers
梯度扩散法药敏纸片生产商说明书审阅的重要性
Mandy Wootton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429
76
One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene
一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成
Christopher J Harmer and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450
77
Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis
接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿
Cristina Gómez-Ayerbe and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456
78
In vitro activity of gepotidacin against Chlamydia trachomatis
吉皮达星对沙眼衣原体的体外活性
Arabella Touati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460
Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期
https://academic.oup.com/jac/issue
Viewpoints（观点）
1
Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？
Aleece MacPhail and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471
2
Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies
靶向治疗时代急性白血病抗真菌预防的重新定义
Marcio Nucci and Johan Maertens
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010
Reviews（综述）
3
Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae
替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展
Meilin Wu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504
4
Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations
两性霉素B脂质体与肾脏安全性：证据回顾及临床考量
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473
5
Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era
奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略
Keiji Okinaka and Joshua T Schiffer
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489
Systematic Reviews（系统综述）
6
Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis
吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析
Taha Ibrahim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469
7
The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review
产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述
Bruna Abdul Ahad Saad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476
8
A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae
决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析
Sambit Kumar Dwibedy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503
9
Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review
促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490
Original Research（论著）
10
Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics
头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究
M B D Nielsen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487
11
Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients
体外膜肺氧合模式对危重患者伏立康唑暴露的影响
Xinrui Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501
12
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案
Dustin Huynh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449
13
Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis
铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析
Karolina Anna Mielko-Niziałek and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453
14
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates
头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性
Carlo Tascini and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467
15
Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands
荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况
Patrick D J Sturm and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475
16
Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant
Acinetobacter baumannii
模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用
Xiaonan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477
17
Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case
加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478
18
The effect of intrauterine exposure to aminoglycosides on neonatal hearing
宫内暴露于氨基糖苷类抗生素对新生儿听力的影响
Daniel Leshin-Carmel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483
19
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies
头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略
Jiaju Zhuo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495
20
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints
采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果
Xinying Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502
21
Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis
肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况
Pascal Chavanet and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474
22
Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi
用于检测广泛耐药伤寒沙门菌的快速分子诊断技术
Emma L Sweeney and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481
23
Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22
性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析
Deepshikha Batheja and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002
24
Real-world evaluation of isavuconazole in children with cancer
伊沙康唑在儿童癌症患者中的现实应用评估
Janine Nijhuis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485
25
Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study
加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究
Joseph Elikem Efui Acolatse and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003
26
Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan
台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性
Guan-Jhou Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488
27
In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates
吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性
Michelle Jayne Cole and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001
28
A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database
基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析
Ye-Lei Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006
29
Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用
Andres Mazariegos Herrera and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014
30
evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology
运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架
Ryan A Hamilton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438
31
First characterization of insertions in the HIV-1 integrase-coding region from people with HIV
首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析
Nhat Quang Tu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491
32
Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae
开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法
Caitlin N Daniels and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493
33
Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats
新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究
Hitesh A Kadu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008
34
Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents
欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究
Marika A de Hoop-Sommen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463
35
Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study
门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究
R C Wilson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484
36
Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy
性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响
Maria Vittoria Cossu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024
37
Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学
Julius J Schmidt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496
38
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制
Yoshinori Yamano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004
39
Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD
基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响
Yao Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500
40
Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia
评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498
Research Letters（研究快讯）
41
False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report
不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告
J Kimmerlin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459
42
Proposal for the nomenclature of tmexCD-toprJ-like gene clusters
关于tmexCD-toprJ样基因簇命名的建议
Chengzhen Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482
43
IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae
IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合
Yan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018
Letter to the Editor（致编辑的信）
44
Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论
Gwénola Marais and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465
45
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply
意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027
ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家）
46
Acknowledgement of Referees
鸣谢审稿专家
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417
CORRECTION（更正）
47
Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492
Journal of Antimicrobial Chemotherapy Volume 81, Issue 3抗菌化疗杂志 81卷 3期
https://academic.oup.com/jac/issue
REVIEW（综述）
1
Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations
缩小欧洲暴露前预防获取差距：面向难以触及（PrEP）人群的公平与创新战略框架
Josep M Llibre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag052, https://doi.org/10.1093/jac/dkag052
2
Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation
成人全身性抗真菌药物的精准给药：治疗药物监测、经验性剂量优化及实施障碍
Daniel B Chastain and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag055, https://doi.org/10.1093/jac/dkag055
3
Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future
细菌DNA拓扑异构酶IV和DNA旋转酶抑制剂：喹诺酮类药物的历史、临床应用及未来潜在替代方案
Daisuke Fukuda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054, https://doi.org/10.1093/jac/dkag054
4
Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions
应对多重耐药肺炎克雷伯菌：当前治疗方案与未来方向
Robiul Islam and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag064, https://doi.org/10.1093/jac/dkag064
SYSTEMATIC REVIEW（系统综述）
5
Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
耐碳青霉烯类鲍曼不动杆菌中金属β-内酰胺酶的全球和区域流行情况：一项系统综述和荟萃分析
Stamatis Karakonstantis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag037, https://doi.org/10.1093/jac/dkag037
Original Research（论著）
6
The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting
三级门诊常规剂量口服环丙沙星对患者QT间期的影响
Weber Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag020, https://doi.org/10.1093/jac/dkag020
7
Bictegravir concentrations in breastmilk of healthy, lactating women without HIV
未感染人类免疫缺陷病毒（HIV）的健康哺乳期女性乳汁中的比克替拉韦浓度
L C van der Wekken-Pas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag022, https://doi.org/10.1093/jac/dkag022
8
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study
从深部部位临床标本中分离出的嗜麦芽窄食单胞菌的治疗及转归：一项双中心回顾性队列研究
Anastasia Saade and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag021, https://doi.org/10.1093/jac/dkag021
9
Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study
万古霉素相关急性肾损伤风险预测模型的建立：一项多中心回顾性研究
Tomoyuki Ishigo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag012, https://doi.org/10.1093/jac/dkag012
10
Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure
HIV-1 整合酶天然多态性 K156N 与 3′PPT 突变在多替拉韦单药治疗失败中的协同作用
Jolieke A T van Osch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag033, https://doi.org/10.1093/jac/dkag033
11
Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies
体重指数和血清白蛋白水平对血液系统恶性肿瘤患者艾沙康唑血浆浓度的影响
Jie Gao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag032, https://doi.org/10.1093/jac/dkag032
12
Pharmacokinetics of cefotaxime and its metabolite desacetyl-cefotaxime to optimize dosing in critically ill children and children with sickle cell disease
用以优化危重症儿童和镰状细胞病儿童给药剂量的头孢噻肟及其代谢产物去乙酰头孢噻肟的药代动力学研究
Seef Abdalla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag019, https://doi.org/10.1093/jac/dkag019
13
Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24
2017 - 2024年加拿大头孢曲松耐药淋病奈瑟菌情况汇总
Robyn Thorington and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag007, https://doi.org/10.1093/jac/dkag007
14
Improving perioperative prophylactic antibiotic prescribing using a novel decision-support tool
使用新型决策支持工具改进围手术期预防性抗生素处方
Mark Mcintyre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag015, https://doi.org/10.1093/jac/dkag015
15
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study
针对产超广谱AmpC酶的阴沟肠杆菌复合群和产气克雷伯菌临床分离株，比较已上市与新一代β-内酰胺类抗生素的抗菌活性：一项多中心研究
Ángel Rodríguez-Villodres and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag034, https://doi.org/10.1093/jac/dkag034
16
Impact of eravacycline on fibrinogen
依拉环素对纤维蛋白原的影响
Emily Stevenson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag030, https://doi.org/10.1093/jac/dkag030
17
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients
原位肝移植受者连续输注头孢他啶-阿维巴坦的药代动力学/药效学胆系分析：一项病例系列研究
Milo Gatti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag009, https://doi.org/10.1093/jac/dkag009
18
Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates
从肺炎克雷伯菌复合群临床分离株队列中鉴定出由mrkH失活介导的与自动聚集相关的碳青霉烯耐受性
Natsuki Yamanaka and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag017, https://doi.org/10.1093/jac/dkag017
19
In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
双联和三联抗菌药物组合对碳青霉烯耐药铜绿假单胞菌生物膜的体外活性研究
Si-Ho Kim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag031, https://doi.org/10.1093/jac/dkag031
20
LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state
LYSC98作为一种新型万古霉素衍生物，对耐受状态下的耐药病原体有效
Xing Xia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag036, https://doi.org/10.1093/jac/dkag036
21
HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV
HIV感染者从富马酸替诺福韦二吡呋酯切换为丙酚替诺福韦后，HBV状态对转氨酶下降的调节作用
Giuseppe Lapadula and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag045, https://doi.org/10.1093/jac/dkag045
22
Pharmacokinetics of colistin in adult critically ill patients in South Africa
南非成人危重症患者中多黏菌素的药代动力学研究
Veshni Pillay-Fuentes Lorente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag011, https://doi.org/10.1093/jac/dkag011
23
Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24)
2019 - 2024年中国10家三级医院临床霉菌对奥罗芬净、马诺盖匹克斯、两性霉素B、三唑类和棘白菌素类抗真菌药的敏感性监测
Su Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag016, https://doi.org/10.1093/jac/dkag016
24
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study
短周期每周三日依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯疗法：一项为期七年的延长研究
Beatriz Borjabad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag040, https://doi.org/10.1093/jac/dkag040
25
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials
美国感染HIV者启动现代抗逆转录病毒治疗方案后患高血压的风险：五项临床试验血压数据汇总分析
Priscilla Y Hsue and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag005, https://doi.org/10.1093/jac/dkag005
26
Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500mg at days 1, 15 and 43 in bone and joint or cardiovascular infection
采用第1、15和43天各1500毫克的三剂量方案对达巴万星（Dalbavancin）在骨关节或心血管感染治疗中的实际药物监测研究
Thomas Lin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag039, https://doi.org/10.1093/jac/dkag039
27
Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries
撒哈拉以南非洲国家全国范围内的HIV耐药及高病毒载量模式
Abubaker Ibrahim Elbur and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf497, https://doi.org/10.1093/jac/dkaf497
28
Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study
老年人常用β-内酰胺类抗生素未达最佳治疗目标的风险因素：一项前瞻性队列研究
Arnaud De Clercq and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag048, https://doi.org/10.1093/jac/dkag048
29
Physiologically based pharmacokinetic modelling to optimize dosing regimen of biapenem in renal impairment and elderly populations
基于生理的药代动力学模型优化肾功能不全及老年人群比阿培南给药方案
Wenyan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf499, https://doi.org/10.1093/jac/dkaf499
30
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study
快速表型抗菌药物敏感性试验指导下的早期目标性治疗对革兰氏阴性菌血流感染危重患者的效果：一项回顾性队列研究
Salvatore Rotundo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag056, https://doi.org/10.1093/jac/dkag056
31
Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK
与新冠肺炎相关的医疗变化对英国苏格兰地区临床大肠杆菌分离株抗生素耐药性的影响：中断时间序列分析
Laura Ciaccio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag049, https://doi.org/10.1093/jac/dkag049
32
Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK–SHOP study
英国和爱尔兰替考拉宁处方与监测的多中心评估：TUcK–SHOP研究
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag038, https://doi.org/10.1093/jac/dkag038
33
Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者发生显著肝纤维化的风险：一项前瞻性队列研究
Win Min Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag053, https://doi.org/10.1093/jac/dkag053
34
A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025
基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库2013 - 2025年数据的碳青霉烯类相关药物警戒分析
Connor Frey and Parham Elmi
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag060, https://doi.org/10.1093/jac/dkag060
35
Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid: data from Landrace pigs
体外膜肺氧合对万古霉素和利奈唑胺药代动力学及组织穿透率的影响：来自长白猪的数据
Huifang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag063, https://doi.org/10.1093/jac/dkag063
36
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes
在既往存在耐药突变的人类免疫缺陷病毒（HIV）感染者中换用比克替拉韦/恩曲他滨/丙酚替诺福韦治疗。来自意大利ARCA队列的数据：BIC-BARRIER研究。比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）换药方案：耐药突变与治疗结果
Laura Pezzati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag035, https://doi.org/10.1093/jac/dkag035
37
A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in Pseudomonas aeruginosa
用于鉴别和评估铜绿假单胞菌对美罗培南异质性耐药风险的二阶段诊断模型
Yali Fan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag061, https://doi.org/10.1093/jac/dkag061
38
Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery
微透析评估庆大霉素在腹部手术中作为二线抗菌预防药物的效果
Quentin Saint-Genis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag071, https://doi.org/10.1093/jac/dkag071
39
Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers
伏立康唑药代动力学及肝毒性的遗传和临床预测因素：聚焦于CYP2C19正常代谢型和中间代谢型
Hui Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag065, https://doi.org/10.1093/jac/dkag065
40
Stakeholder perspectives on the offer and acceptance of self-administration of outpatient parenteral antimicrobial therapy: a qualitative study
利益相关者对提供和接受门诊患者自行注射抗菌药物治疗的看法：一项定性研究
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag068, https://doi.org/10.1093/jac/dkag068
41
Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort
当前髋关节和膝关节置换术中氯唑西林预防性用药剂量指南是否充分？来自一项前瞻性瑞典队列研究的证据
Katja Wallander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag067, https://doi.org/10.1093/jac/dkag067
42
Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China
治疗前HIV药物耐药性对开始接受抗逆转录病毒治疗患者的死亡率、失访率和病毒抑制率的影响以及遗传传播网络：中国西南地区一项观察性队列研究
Litai Qin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag073, https://doi.org/10.1093/jac/dkag073
RESEARCH LETTER（研究快讯）
43
Varicella and varicella zoster virus meningoencephalitis in a diffuse large B-cell lymphoma patient after chimeric antigen receptor-T-cell therapy
嵌合抗原受体T细胞疗法后，弥漫性大B细胞淋巴瘤患者发生水痘及水痘-带状疱疹病毒脑膜脑炎
Yan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag041, https://doi.org/10.1093/jac/dkag041
44
The ‘double hit’ on dalbavancin pharmacokinetics: hypertriglyceridaemia and augmented renal clearance in a child with glycogen storage disease type Ib
糖原累积病Ib型患儿中，高甘油三酯血症和肾清除率增加对达巴万星药代动力学的“双重打击”
Bianca Monti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag028, https://doi.org/10.1093/jac/dkag028
45
Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis
Tn7860，粪肠球菌中携带OptrA基因的一种新型染色体假复合转座子
Francesca Romana Massacci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag046, https://doi.org/10.1093/jac/dkag046
46
HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir
HIV感染者换用卡博特韦（cabotegravir）联合利匹韦林（rilpivirine）治疗后乙肝病毒再激活：切勿忽视病毒储存库
Rémi Rouget and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag050, https://doi.org/10.1093/jac/dkag050
47
An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data
一例涉及血管移植物的无法手术的纵隔感染，采用每周一次的奥利万星作为慢性抑制疗法。附药代动力学数据的病例报告
Pierangelo Chinello and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag013, https://doi.org/10.1093/jac/dkag013
48
Evaluation of the Carbapenemase Detection Kit (Colloidal Gold; Macro & Micro Test): a new immunochromatographic assay for rapid detection of carbapenemases in Enterobacterales
碳青霉烯酶检测试剂盒（胶体金法；宏基因与微基因检测法）评估：一种用于快速检测肠杆菌目细菌中碳青霉烯酶的新型免疫层析法
Hippolyte De Swardt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag066, https://doi.org/10.1093/jac/dkag066
49
Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence
头孢氨苄在英国急性肾盂肾炎治疗中的应用：给药、断点和临床证据方面尚未解决的挑战
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag051, https://doi.org/10.1093/jac/dkag051
LETTERS TO THE EDITOR（致编辑的信）
50
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
评论：意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Chris Kenyon
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag025, https://doi.org/10.1093/jac/dkag025
51
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply
来特莫韦暴露的造血细胞移植受者发生EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加：答复权
Jose F Camargo and Anthony D Anderson
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag043, https://doi.org/10.1093/jac/dkag043
52
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply
意大利米兰市使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性性传播感染的抗菌药物使用情况——答复权声明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag026, https://doi.org/10.1093/jac/dkag026
53
Comment on: Artificial intelligence for improving decision-making in bacterial infection management
述评：人工智能在细菌感染管理决策中的优化作用
Daniele Roberto Giacobbe
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag078, https://doi.org/10.1093/jac/dkag078
CORRECTION（更正）
54
Correction to: Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study
更正：抗菌药物耐药性流行率的贝叶斯估计：一项数学建模研究
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf494, https://doi.org/10.1093/jac/dkaf494
55
Correction to: National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
更正：哥伦比亚具有全国代表性的治疗前HIV耐药性调查：使用下一代测序技术分析抗逆转录病毒耐药相关突变
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag057, https://doi.org/10.1093/jac/dkag057
Journal of Antimicrobial Chemotherapy Volume 81, Issue 4抗菌化疗杂志81卷 4期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
GARROD LECTURE（加罗德讲座）
1
Garrod lecture: achieving the UNGA AMR mortality reduction goals
加罗德讲座：实现联合国大会抗菌药物耐药性死亡率降低目标
Ramanan Laxminarayan
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag082, https://doi.org/10.1093/jac/dkag082
REVIEW（综述）
2
25 years of improvement in mortality in invasive aspergillosis in haematology patients: will it be sustained or is it under threat?
侵袭性曲霉病血液病患者25年死亡率改善情况：这种改善能否持续，还是正受到威胁？
Johan A Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag077, https://doi.org/10.1093/jac/dkag077
3
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hit
针对锥虫病的从高质量潜在客户和药物开发候选者出发的战略发现路线图。第二部分：从分子到确证活性分子
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag110, https://doi.org/10.1093/jac/dkag110
VIRTUAL ROUNDTABLE（虚拟圆桌会议）
4
Diagnosis and risk factors for invasive mould disease—a round table discussion on directing antifungal therapy according to the available evidence
侵袭性霉菌病的诊断与危险因素——根据现有证据指导抗真菌治疗的圆桌讨论
Ana Alastruey-Izqueirdo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag062, https://doi.org/10.1093/jac/dkag062
EDITORIALS, MESSAGES FROM THE OUTGOING AND INCOMING EDITORS-IN-CHIEF（社论、离任与就任主编寄语）
5
Message from the incoming Editor-in-Chief of JAC
《抗菌化疗杂志》就任主编寄语
Monica A Slavin
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf479, https://doi.org/10.1093/jac/dkaf479
6
Message from the outgoing Editor-in-Chief
离任主编寄语
J Peter Donnelly
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf480, https://doi.org/10.1093/jac/dkaf480
REVIEW（综述）
7
Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro, ex vivo and in vivo systems
用于药代动力学和药效学研究的实验性生物膜模型：连接体外、离体和体内系统
Stephanie Supparitsch and Markus Zeitlinger
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag091, https://doi.org/10.1093/jac/dkag091
8
Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics
感染性坏死性胰腺炎的抗菌治疗：微生物学、抗菌药物耐药性及药代动力学
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag092, https://doi.org/10.1093/jac/dkag092
9
Continuous linezolid infusion: the new way to dose, the old risks to fear
持续输注利奈唑胺：新的给药方式，仍需警惕旧有风险
Daniel Muñoz-Pichuante and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag100, https://doi.org/10.1093/jac/dkag100
10
Alignment of national standard treatment guidelines with WHO AWaRe recommendations for adult primary care infectious diseases: implications for antimicrobial stewardship
将国家标准治疗指南与世卫组织（WHO）针对成人初级保健传染病的“慎用、监测、备用”（AWaRe）推荐意见相统一：对抗菌药物管理的影响
Huda Arooj and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag099, https://doi.org/10.1093/jac/dkag099
SYSTEMATIC REVIEW（系统综述）
11
Healthcare providers’ experiences in caring for MDRO carriers with a focus on the moral dimensions of care: a systematic review
医疗服务提供者护理多重耐药菌（MDRO）携带者的经历——聚焦护理中的道德维度：一项系统综述
Carlijn Damsté and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag059, https://doi.org/10.1093/jac/dkag059
12
Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review
奥利他万星药代动力学/药效学目标的外推用以指导治疗药物监测：一项系统综述
Giammarco Baiardi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag117, https://doi.org/10.1093/jac/dkag117
ORIGINAL RESEARCH（论著）
13
Beyond plasma: defining the translation value of epithelial lining fluid exposure profiles for the treatment of pneumonia
超越血浆：明确上皮衬里液暴露谱对肺炎治疗的转化价值
Yakun Fu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf458, https://doi.org/10.1093/jac/dkaf458
14
Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study
负荷剂量β-内酰胺类药物治疗非重症监护病房患者产KPC肺炎克雷伯菌血流感染的疗效影响：一项现实研究
Luisa Frallonardo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag087, https://doi.org/10.1093/jac/dkag087
15
Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro
雷扎芬净在体外对真菌生物膜表现出抗生物膜特性
Hafsa Abduljalil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag058, https://doi.org/10.1093/jac/dkag058
16
Vancomycin resistance predicts increased mortality in patients with Enterococcus faecium bloodstream infections: a six-year experience at a large tertiary care Italian hospital
万古霉素耐药性可预测屎肠球菌血流感染患者死亡率增加：意大利一家大型三级医院六年来的经验
Lucia Graziani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag069, https://doi.org/10.1093/jac/dkag069
17
Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database
氟喹诺酮类药物与惊恐发作风险：基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库中个体病例安全报告的系统综述和比例失衡分析
Keeirah Hiertika Raguram and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag083, https://doi.org/10.1093/jac/dkag083
18
Cefuroxime concentrations in facial artery musculomucosal flap, buccal submucosa, subcutaneous tissue, and plasma following bolus or continuous infusion in patients undergoing oral cancer resection: a randomized clinical microdialysis study
在接受口腔癌切除术的患者中，采用随机临床微透析研究，探究头孢呋辛在面动脉肌黏膜瓣、颊黏膜下层、皮下组织和血浆中的浓度（团注或持续输注后）
Johanne Ravn Hansen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag085, https://doi.org/10.1093/jac/dkag085
19
Infection point of care tests bridge the experience gap of antibiotic STOP decisions: clinicians versus students
感染即时检测可弥补抗生素停药决策方面的经验差距：临床医生与学生对比
Archit Singhal and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf486, https://doi.org/10.1093/jac/dkaf486
20
Functional analysis of a novel macrolide–lincosamide resistance gene erm(57) in Cutibacterium avidum
痤疮丙酸杆菌中一种新型大环内酯 - 林可酰胺类耐药基因erm(57)的功能分析
Juri Koizumi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag029, https://doi.org/10.1093/jac/dkag029
21
HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial
莱索托和坦桑尼亚病毒血症儿童及青少年中的HIV耐药性：GIVE MOVE试验的嵌套分析
Christof Manuel Schönenberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag070, https://doi.org/10.1093/jac/dkag070
22
Identification and assessment of paediatric cefepime-induced neurotoxicity in a retrospective cohort of paediatric intensive care patients
在儿科重症监护患者回顾性队列中识别和评估儿科头孢吡肟诱导的神经毒性
Kathryn Pavia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag075, https://doi.org/10.1093/jac/dkag075
23
Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database
整合酶抑制剂和非核苷类逆转录酶抑制剂相关不良事件的优先级排序：基于FAERS数据库数据的比例失衡分析
Gao-yang Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag074, https://doi.org/10.1093/jac/dkag074
24
Clinical and immunovirological status in children, adolescents and young adults with early-life-acquired HIV: a Spanish multi-cohort analysis since 2020
自2020年以来西班牙多队列分析中，儿童、青少年及青年时期感染HIV者的临床及免疫病毒学状态
Laura Tarancon-Diez and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag079, https://doi.org/10.1093/jac/dkag079
25
Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study
接受体外膜肺氧合治疗的危重成年患者美罗培南的群体药代动力学——一项ASAP ECMO研究
Mohd H Abdul–Aziz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag090, https://doi.org/10.1093/jac/dkag090
26
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing
2022年至2024年意大利流行HIV-1亚型间传播耐药性的评估：通过下一代测序技术进行的精细分析
Daniele Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag084, https://doi.org/10.1093/jac/dkag084
27
Characterization of efflux pump channel of florfenicol for resistance-enhancing variant RE-CmeABC in Campylobacter
耐药增强型变异体RE-CmeABC中氟苯尼考外排泵通道在弯曲菌中的特性研究
Hong Yao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag047, https://doi.org/10.1093/jac/dkag047
28
Genomic characterization of colistin heteroresistance in Acinetobacter baumannii: Evidence for lpxD deletion and collateral sensitivity
鲍曼不动杆菌中黏菌素异质性耐药的基因组特征：lpxD缺失及附带敏感性的证据
Banu Sancak and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag076, https://doi.org/10.1093/jac/dkag076
29
Sustaining stewardship: longitudinal evaluation of an integrated antimicrobial programme in the ICU
持续管理：重症监护室（ICU）综合抗菌药物管理项目的纵向评估
Ashmitha Thomas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag086, https://doi.org/10.1093/jac/dkag086
30
Global dissemination of optrA-mediated linezolid resistance in enterococci
利奈唑胺耐药性基因optrA介导的肠球菌在全球的传播
Jia Qi Beh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag089, https://doi.org/10.1093/jac/dkag089
31
Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing
利用肠外头孢菌素敏感性试验预测大肠杆菌血培养分离株对口服头孢菌素的敏感性
Tho H Pham and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag093, https://doi.org/10.1093/jac/dkag093
32
The pharmacodynamics of polymyxin B in Acinetobacter baumannii in murine thigh and lung infection models
在小鼠大腿和肺部感染模型中多粘菌素B对鲍曼不动杆菌的药效动力学研究
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag097, https://doi.org/10.1093/jac/dkag097
33
Genomic insights into the tmexCD-toprJ: plasmid-mediated evolution, dissemination and diversity in bacterial populations
关于tmexCD-toprJ的基因组见解：质粒介导的细菌群体进化、传播与多样性
Lilan Wan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag107, https://doi.org/10.1093/jac/dkag107
34
Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study
初治患者基线耐药突变与多替拉韦病毒学应答：一项多中心下一代测序（NGS）研究
Alexy Inciarte and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag080, https://doi.org/10.1093/jac/dkag080
35
Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study
非洲非B型HIV-1毒株中与多替拉韦（DTG）基因型耐药相关的新型整合酶突变：DTG耐药研究
Nuri Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag088, https://doi.org/10.1093/jac/dkag088
36
Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model
体外宫颈阴道HIV预防模型的药理学评估
Lindsey B Collins and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag103, https://doi.org/10.1093/jac/dkag103
37
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictions
NOSO-502药效学指数的幅度：病原体清除、耐药性出现和人体剂量预测
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag106, https://doi.org/10.1093/jac/dkag106
38
Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales?
替莫西林：治疗第三代头孢菌素耐药肠杆菌目引起的骨关节感染的一种替代疗法？
Louise Piquart and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag105, https://doi.org/10.1093/jac/dkag105
39
Metallo-β-lactamase–producing Enterobacterales: cyanide-containing efflux pump inhibitors as potential dual-activity inhibitors
产金属β-内酰胺酶的肠杆菌科细菌：含氰化物的外排泵抑制剂作为潜在的双活性抑制剂
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag122, https://doi.org/10.1093/jac/dkag122
40
Outer membrane vesicles transmit blaNDM-5 and package metallo-β-lactamases to promote antibiotic resistance in Escherichia coli
外膜囊泡传递blaNDM-5并包装金属β-内酰胺酶以促进大肠杆菌的抗生素耐药性
Ting-Yin Lu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag123, https://doi.org/10.1093/jac/dkag123
41
Characterization of a ST412-K57 colistin-resistant hypervirulent Klebsiella pneumoniae strain of chicken origin
一株鸡源ST412-K57多粘菌素耐药高毒力肺炎克雷伯菌的特征分析
Qiu Xu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag114, https://doi.org/10.1093/jac/dkag114
42
Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study
奥罗芬明与唑类抗真菌药联合使用：2期挽救治疗研究结果
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag118, https://doi.org/10.1093/jac/dkag118
RESEARCH LETTER（研究快讯）
43
Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion
母体病毒得到抑制，婴儿仍发生HIV传播：一例断奶后血清转阳病例
Shadia Nakalema and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag072, https://doi.org/10.1093/jac/dkag072
44
Urinary antigen–negative Legionella pneumonia in critically ill patients: value of systematic molecular testing for optimal antimicrobial therapy
危重患者中尿抗原阴性军团菌肺炎：系统分子检测在优化抗菌治疗中的价值
Livia Foglia Manzillo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag101, https://doi.org/10.1093/jac/dkag101
45
Contribution of SHV-1 overexpression to carbapenem resistance in a Klebsiella pneumoniae clinical isolate
SHV-1过表达对某株肺炎克雷伯菌临床分离株碳青霉烯类抗生素耐药性的影响
Céline Plainvert and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag108, https://doi.org/10.1093/jac/dkag108
LETTER TO THE EDITOR（致编辑的信）
46
Comment on: Possible increased risk of Epstein–Barr virus (EBV) infection and posttransplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
评论：接受莱特莫韦治疗的造血细胞移植受者中，EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加
Jan Styczynski
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag042, https://doi.org/10.1093/jac/dkag042
47
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis users in Milan, Italy
评论：意大利米兰地区使用多西环素暴露后预防措施人群中针对细菌性性传播感染的抗菌药物使用情况
Luca Bortolani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag023, https://doi.org/10.1093/jac/dkag023
48
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes—right to reply
使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净药物治疗监测的回顾性分析——答复权
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag095, https://doi.org/10.1093/jac/dkag095
49
Comment on: Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched-cohort study
评论：替莫西林与其他静脉注射β-内酰胺类抗生素治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究
Shanshan Ru and Yingzhe Zhang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag096, https://doi.org/10.1093/jac/dkag096
50
Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
评论：长效糖肽类抗生素：对于最需要它们的患者，获取的障碍是什么，如何克服？
Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag102, https://doi.org/10.1093/jac/dkag102
51
Comment on ‘Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes’
评论：“对使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净的药理学治疗监测的回顾性分析”
Julien Massol and Frédéric Baud
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag094, https://doi.org/10.1093/jac/dkag094
52
Comment on: ‘Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp’
对“除塞拉蒂亚属（Serratia spp）外肠杆菌目所致心内膜炎的流行病学和治疗”的评论
Gianpiero Tebano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag098, https://doi.org/10.1093/jac/dkag098
53
‘Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–2021-right-to-reply’
“比较肺炎球菌疫苗的血清型覆盖率——PCV21（V116，一种新型21价结合肺炎球菌疫苗）与加拿大成人患者中导致侵袭性肺炎球菌疾病的其8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学：SAVE研究，2018 - 2021年——回应”
John J Schellenberg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag126, https://doi.org/10.1093/jac/dkag126
54
Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus
评论：奥罗芬明与伏立康唑对烟曲霉的体外拮抗作用
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag119, https://doi.org/10.1093/jac/dkag119
55
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.: right-to-reply
除塞氏杆菌属外肠杆菌科细菌所致心内膜炎的流行病学和治疗：回应
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag121, https://doi.org/10.1093/jac/dkag121
Journal of Antimicrobial Chemotherapy Volume 81, Issue 5抗菌化疗杂志81卷 5期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
REVIEW（综述）
1
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stage
针对动基体病的高质量先导化合物及药物开发候选物的战略发现路线图。第一部分：背景介绍
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag109, https://doi.org/10.1093/jac/dkag109
REVIEW（综述）
2
Pathophysiology, risk factors and clinical management for polymyxin-associated acute kidney injury
多粘菌素相关急性肾损伤的病理生理学、危险因素及临床治疗
Simiao Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag132, https://doi.org/10.1093/jac/dkag132
SYSTEMATIC REVIEW（系统综述）
3
Definitions and rates of treatment failure in females with uncomplicated urinary tract infection: a systematic literature review
女性单纯性尿路感染治疗失败的定义及发生率：一项系统文献综述
Meghan E Luck and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag112, https://doi.org/10.1093/jac/dkag112
4
Therapeutic drug monitoring and the role of pharmacokinetics/pharmacodynamics in optimizing beta-lactam antibiotic dosing for deep-seated infections: a systematic review
在针对深部感染的β-内酰胺类抗生素优化给药方案中治疗药物监测以及药代动力学/药效学的作用：一项系统综述
Cassandra Vale and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag142, https://doi.org/10.1093/jac/dkag142
ORIGINAL RESEARCH（论著）
5
Optimizing cloxacillin prophylaxis in hip and knee arthroplasty based on population pharmacokinetics of unbound plasma concentrations
基于游离血浆浓度群体药代动力学优化髋关节和膝关节置换术中的氯唑西林预防用药方案
Gustaf Beijer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag116, https://doi.org/10.1093/jac/dkag116
6
The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat
大鼠静脉注射[14C]奥洛罗芬后的组织分布及药代动力学研究
Derek Law and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag120, https://doi.org/10.1093/jac/dkag120
7
Insights from the WHO Tricycle-aligned Fleming Fund EQASIA External Quality Assessment (EQA) programme detecting ESBL-, AmpC- and carbapenemase-producing Escherichia coli in South and South-East Asia
世界卫生组织三轮车项目（Tricycle）协同的弗莱明基金南亚和东南亚地区外部质量评估（EQASIA EQA）计划在检测南亚和东南亚地区产超广谱β-内酰胺酶（ESBL）、AmpC酶和碳青霉烯酶的大肠埃希菌方面的见解
Hiba Al-Mir and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag129, https://doi.org/10.1093/jac/dkag129
8
The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIV
HIV感染者肌内注射长效卡博特韦和利匹韦林后的血浆及细胞内暴露情况
Micol Ferrara and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag113, https://doi.org/10.1093/jac/dkag113
9
In vitro synergistic activity of minocycline and biapenem against cefiderocol-resistant New Delhi metallo-β-lactamase-producing Enterobacterales
米诺环素与比阿培南在体外对产新德里金属β-内酰胺酶且对头孢地尔耐药的肠杆菌科细菌的协同作用
Takashi Okanda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag128, https://doi.org/10.1093/jac/dkag128
10
Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort
产超广谱β-内酰胺酶大肠埃希菌菌血症的死亡风险：基于PROBAC队列的综合分析
Paula Olivares-Navarro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag130, https://doi.org/10.1093/jac/dkag130
11
Molecular mechanism of envZ regulating β-lactam antibiotic resistance and virulence in Escherichia coli
EnvZ调控大肠埃希菌β-内酰胺类抗生素耐药性及毒力的分子机制
Kun Yang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag104, https://doi.org/10.1093/jac/dkag104
12
In vitro activity of amoxicillin combined with oral cephalosporins against endocarditis-associated E. faecalis clinical isolates
阿莫西林联合口服头孢菌素针对心内膜炎相关粪肠球菌临床分离株的体外活性
David Luque Paz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag127, https://doi.org/10.1093/jac/dkag127
13
Genome-wide association studies builds a predictive model and reveals novel resistance features for macrolide-resistant Bordetella pertussis
全基因组关联研究构建预测模型并揭示大环内酯类耐药百日咳鲍特菌的新耐药特征
Jialiang Chen and Guowei Liang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag131, https://doi.org/10.1093/jac/dkag131
14
Real-world validation of a reduced-dose continuous infusion cefepime regimen: pharmacodynamic target attainment, efficacy and neurotoxicity
减量持续静脉输注头孢吡肟方案的实际应用验证：药效学目标达成情况、疗效及神经毒性
Kieffer Korvin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag138, https://doi.org/10.1093/jac/dkag138
15
Cross-species and cross-border spread of aph(3′)-ia-mediated neomycin resistance in Escherichia coli from animals: a genomic perspective
从基因组角度研究动物源大肠杆菌中aph(3′)-ia介导的新霉素耐药性的跨物种和跨国传播
Mattia Pirolo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag143, https://doi.org/10.1093/jac/dkag143
16
Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance
美国烟曲霉临床分离株集合中cyp51A变异体的流行情况及其对三唑类抗真菌药物耐药性作用的比较分析
Luisa Fernanda Gómez Londoño and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag124, https://doi.org/10.1093/jac/dkag124
17
In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance
达托霉素联合头孢洛林对高水平氨基糖苷类耐药及非耐药粪肠球菌所致实验性心内膜炎的体内外疗效研究
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag136, https://doi.org/10.1093/jac/dkag136
18
Pharmacokinetics of a three-dose regimen of intramuscular benzathine penicillin G in pregnant women with syphilis
三剂苄星青霉素G肌内注射方案在妊娠期梅毒患者中的药代动力学研究
Eshetie Melese Birru and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag145, https://doi.org/10.1093/jac/dkag145
19
Cefiderocol resistance mediated by mutation of the miniconductance mechanosensitive channel MscM in Klebsiella oxytoca
由产气克雷伯菌中微小电导机械敏感通道MscM发生突变所介导的头孢地尔耐药性
Pia Turowski and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag147, https://doi.org/10.1093/jac/dkag147
20
The veterinary clinic backyard lawn used for relief walks of hospitalized dogs is a hotspot for OXA-type carbapenemases in multiple Enterobacterales
兽医诊所后院供住院犬只散步的草坪是多种肠杆菌科细菌中OXA型碳青霉烯酶的传播热点区域
Yvonne Spahr and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag144, https://doi.org/10.1093/jac/dkag144
21
Pharmacokinetics of cefazolin in bariatric surgery patients: a preoperative perspective
头孢唑林在减肥手术患者中的药代动力学：术前视角
Alexandra Porlier and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag150, https://doi.org/10.1093/jac/dkag150
RESEARCH LETTERS（研究快讯）
22
Plasmid-encoded FRI-10 carbapenemase harboured by non-Enterobacter species isolated from a wastewater sample in Tokyo, Japan
从日本东京废水样本中分离出的非肠杆菌科物种携带质粒编码的FRI-10碳青霉烯酶
Kou Murakami and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag133, https://doi.org/10.1093/jac/dkag133
23
Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variants
头孢吡肟/恩美唑巴坦与美罗培南、哌拉西林、哌拉西林/他唑巴坦、西他沙星和磷霉素针对携带blaKPC等位基因变体的肺炎克雷伯菌的协同作用
Alice Crema and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag141, https://doi.org/10.1093/jac/dkag141
24
MRSA and carbapenem-resistant Acinetobacter baumannii on the fall: successful infection prevention and control in Chilean ICUs
耐甲氧西林金黄色葡萄球菌和耐碳青霉烯类鲍曼不动杆菌数量下降：智利重症监护病房感染预防与控制的成功案例
Patricio Ross and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag146, https://doi.org/10.1093/jac/dkag146
LETTER TO THE EDITOR（致编辑的信）
25
Comment on: Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic–pharmacodynamic modelling in adults and infants
评论：基于模型的评估VRC07-523LS在婴儿中的给药剂量——基于成人和婴儿群体药代动力学-药效学模型
Wanhua Qiu
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag139, https://doi.org/10.1093/jac/dkag139
26
Comment on: Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–21
评论：比较含21种血清型的肺炎球菌疫苗PCV21（V116）（一种新型21价结合肺炎球菌疫苗）的血清型覆盖范围，以及2018 - 2021年SAVE研究中导致加拿大成年患者侵袭性肺炎球菌疾病的8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学情况
Gokul Raj Pullagura and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag125, https://doi.org/10.1093/jac/dkag125
27
Comment on: Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates
评论：肉鸡源和人临床来源肠球菌分离株中NarAB的不同种群结构和基因组背景
Alex Wong
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag134, https://doi.org/10.1093/jac/dkag134
28
Distinct population structure and genomic context of narAB between broiler and human clinical Enterococcus isolates—authors’ response
肉鸡源和人临床来源肠球菌分离株中narAB的不同种群结构和基因组背景——作者回复
Jayanth Balakuntla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag135, https://doi.org/10.1093/jac/dkag135
Journal of Antimicrobial Chemotherapy Volume 81, Issue 6抗菌化疗杂志81卷 6期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
REVIEW（综述）
1
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 3: from lead towards a drug development candidate
针对动基体疾病高质量先导化合物和药物开发候选物的战略发现路线图。第三部分：从先导化合物到药物开发候选物
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag111, https://doi.org/10.1093/jac/dkag111
ORIGINAL RESEARCH（原创研究）
2
Population pharmacokinetics and probability of target attainment of tigecycline in critically ill children
危重患儿中替加环素（Tigecycline）的群体药代动力学及目标达成概率研究
Wenjuan Hu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag156, https://doi.org/10.1093/jac/dkag156
3
Phenotypic and genotypic characterization of HMB-3, a metallo-beta-lactamase from Pseudomonas asiatica
假单胞菌属亚洲种（Pseudomonas asiatica）中金属β-内酰胺酶HMB-3的表型和基因型特征
Jacqueline Findlay and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag148, https://doi.org/10.1093/jac/dkag148
4
Early adequate linezolid concentrations and clinical outcomes in confirmed Gram-positive infections: the role of therapeutic drug monitoring
确诊的革兰氏阳性菌感染中早期达到适宜利奈唑胺浓度与临床预后的关系：治疗药物监测的作用
Daniel Fresán and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag137, https://doi.org/10.1093/jac/dkag137
5
Monte Carlo simulations identify suboptimal PK/PD target attainment with standard maribavir dosing
蒙特卡洛模拟表明标准剂量马立巴韦的药动学/药效学靶标达成情况欠佳
Yeleen Fromage and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag153, https://doi.org/10.1093/jac/dkag153
6
Exploring the pharmacokinetic mechanisms that affect bictegravir exposure during pregnancy
探究妊娠期间影响比克替拉韦暴露的药代动力学机制
L van der Wekken-Pas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag159, https://doi.org/10.1093/jac/dkag159
7
Artificial intelligence for analysing antibiotic use: an exploratory study in a tertiary care paediatric hospital in Italy
人工智能用于分析抗生素使用情况：意大利一家三级儿科医院的探索性研究
Elio Castagnola and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag162, https://doi.org/10.1093/jac/dkag162
8
Antimicrobial activity of aztreonam–avibactam against KPC variant-producing Klebsiella pneumoniae with ceftazidime–avibactam resistance
氨曲南-阿维巴坦对产KPC变异体且对头孢他啶-阿维巴坦耐药的肺炎克雷伯菌的抗菌活性
Jingchun Kong and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag152, https://doi.org/10.1093/jac/dkag152
9
Highly transformable Haemophilus influenzae as a potential amplifier of quinolone resistance dissemination
高转化型流感嗜血杆菌作为喹诺酮耐药性传播的潜在放大器
Takeaki Wajima and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag160, https://doi.org/10.1093/jac/dkag160
10
Comparative nephrotoxicity of polymyxin B versus colistin: evidence from ensemble learning and propensity score matching
多黏菌素B与黏菌素的肾毒性比较：来自集成学习和倾向评分匹配的证据
Murat Özdede and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag044, https://doi.org/10.1093/jac/dkag044
11
Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections
模拟医院获得性单菌革兰氏阴性菌血流感染早期与晚期开始恰当抗生素治疗的对照试验
Abdullah T Aslan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag161, https://doi.org/10.1093/jac/dkag161
12
Flufenamic acid resensitizes MRSA to gentamicin through synergistic ion modulation
氟苯尼考通过协同离子调节使MRSA对庆大霉素重新敏感
Xiaomin Ren and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag154, https://doi.org/10.1093/jac/dkag154
13
Description of OXA-244 carbapenemase-producing Escherichia coli in farm animals in The Netherlands, 2024
2024年荷兰农场动物中OXA-244碳青霉烯酶产大肠杆菌的描述
K T Veldman and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag155, https://doi.org/10.1093/jac/dkag155
14
Clinical outcomes of beta-bactam monotherapy versus beta-lactam plus azithromycin in hospitalized patients with community-acquired pneumoniae
β-内酰胺类单药治疗与β-内酰胺类联合阿奇霉素治疗社区获得性肺炎住院患者的临床预后比较
Ilona Zhygalova Zhygalova and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag158, https://doi.org/10.1093/jac/dkag158
15
‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort
"不遗余力"：ODOACRE队列中多替拉韦+拉米夫定（DTG+3TC）作为转换方案长达10年的有效性、耐受性及代谢安全性结果
Arturo Ciccullo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag172, https://doi.org/10.1093/jac/dkag172
16
Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture
新型侧向流免疫层析检测试剂Certest ResisCheck® Carbapenemases用于革兰氏阴性菌培养物中碳青霉烯酶快速检测与鉴别的评估
Laura Monge-Olivares and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag149, https://doi.org/10.1093/jac/dkag149
17
Temocillin efficacy and emergence of resistance in Enterobacter cloacae Complex in a murine peritonitis model
替莫西林对产气肠杆菌复合群的疗效及耐药性演变：小鼠腹膜炎模型研究
N Alanbari and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag151, https://doi.org/10.1093/jac/dkag151
18
Temporal association between aerosolized colistin use and colistin resistance in the ICU: a time-series analysis
ICU中雾化粘菌素使用与粘菌素耐药之间的时间关联：一项时间序列分析
Weechang Kang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag169, https://doi.org/10.1093/jac/dkag169
19
Can antimicrobial stewardship programmes be implemented during an armed conflict? A retrospective interventional cohort study
武装冲突期间能否实施抗菌药物管理计划？一项回顾性干预性队列研究
Hailie D Uren and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag115, https://doi.org/10.1093/jac/dkag115
20
Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy
伏立康唑治疗与CYP2C19表型：识别可能需要替代抗真菌治疗的患者
Eman Wehbe and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag168, https://doi.org/10.1093/jac/dkag168
21
Impact of cardiopulmonary bypass on cefuroxime plasma and interstitial tissue concentrations in patients undergoing cardiac bypass surgery—a prospective controlled clinical trial
体外循环对心脏旁路手术患者头孢呋辛血浆及组织间质浓度的影响——一项前瞻性对照临床试验
Stefanie Nothofer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag171, https://doi.org/10.1093/jac/dkag171
22
Population pharmacokinetic analysis and dosing regimen optimization of eravacycline in critically ill patients with carbapenem-resistant Acinetobacter baumannii pneumonia
对碳青霉烯耐药鲍曼不动杆菌肺炎危重患者中埃拉环素的药代动力学分析及给药方案优化
Luqi Lou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag178, https://doi.org/10.1093/jac/dkag178
23
Durability and mechanistic performance of aztreonam/avibactam versus aztreonam plus ceftazidime/avibactam against Stenotrophomonas maltophilia complex
氨曲南/阿维巴坦与氨曲南联合头孢他啶/阿维巴坦对抗嗜麦芽窄食单胞菌复合群的耐久性和机制性能比较
Ashlan J Kunz Coyne and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag177, https://doi.org/10.1093/jac/dkag177
24
High-dose daptomycin for the treatment of invasive infections due to Enterococcus faecalis isolates with intermediate susceptibility
高剂量达托霉素治疗粪肠球菌中介敏感株所致侵袭性感染的疗效
Sidney Drake and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag179, https://doi.org/10.1093/jac/dkag179
25
Updated mapping of Plasmodium falciparum kelch13 gene polymorphisms in Madagascar, 2024
2024年马达加斯加恶性疟原虫kelch13基因多态性的最新图谱更新
Camille Roesch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag181, https://doi.org/10.1093/jac/dkag181
26
Efficacy of ceftazidime/avibactam against 10 clinical isolates of Pseudomonas aeruginosa in icodextrin-based peritoneal dialysis solution and patient-derived dialysate
头孢他啶/阿维巴坦针对icodextrin基腹膜透析液及患者来源透析液中10株铜绿假单胞菌临床分离株的抗菌活性
Stephanie Supparitsch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag185, https://doi.org/10.1093/jac/dkag185
27
Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes
头孢德罗对PERSEUS研究中多重耐药分离株的抗菌活性：头孢德罗最低抑菌浓度与临床预后之间的关系
Rafael Cantón and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag164, https://doi.org/10.1093/jac/dkag164
28
Class 1 DISARM system in restriction of conjugative carbapenemase-encoding plasmids in Klebsiella pneumoniae sequence type 23
1类DISARM系统对肺炎克雷伯菌ST23中接合型碳青霉烯酶编码质粒的限制作用
Qingqing Du and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag167, https://doi.org/10.1093/jac/dkag167
29
Acute kidney injury following amikacin therapy: a retrospective cohort study
阿米卡星治疗后急性肾损伤：一项回顾性队列研究
Iris Zohar and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag188, https://doi.org/10.1093/jac/dkag188
30
Performance of EUCAST disc diffusion and supplementary methods to detect reduced susceptibility to linezolid in enterococci— the NordicAST LRE-study
EUCAST纸片扩散法及补充方法检测肠球菌利奈唑胺低敏感性的表现——NordicAST LRE研究
Bjørg Christina Haldorsen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag174, https://doi.org/10.1093/jac/dkag174
31
In vitro exposure to non-antipseudomonal antibiotics (NAPA) induces Pseudomonas aeruginosa resistance to antipseudomonal antibiotics (APA)
体外暴露于非抗假单胞菌抗生素（NAPA）可诱导铜绿假单胞菌对抗假单胞菌抗生素（APA）产生耐药性
David Lasry and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag182, https://doi.org/10.1093/jac/dkag182
32
Sub-inhibitory polyether ionophores enhance resistance plasmid transfer and transiently perturb the broiler gut resistome
亚抑制浓度的聚醚离子载体可促进耐药质粒转移并暂时扰乱肉鸡肠道耐药组
Jingyue Yang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag190, https://doi.org/10.1093/jac/dkag190
33
Influence of a putative TonB-dependent receptor on cefiderocol susceptibility in clinical Enterobacter hormaechei isolates
推测的TonB依赖性受体对临床肠杆菌hormaechei分离株中头孢地尔敏感性的影响
Pia Turowski and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag193, https://doi.org/10.1093/jac/dkag193
RESEARCH LETTERS（研究快报）
34
Early bictegravir failure and emergence of R263K-mediated class-wide HIV integrase inhibitors resistance linked to over-the-counter supplement use
比克替拉韦早期治疗失败与R263K介导的与非处方补充剂使用相关的全类HIV整合酶抑制剂耐药的出现
Elisa Minacori and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag157, https://doi.org/10.1093/jac/dkag157
35
Environmental benefits of switching from intravenous to oral administration of ciprofloxacin
环丙沙星从静脉给药转换为口服给药的环境效益
Nicolas De Jaegher and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag163, https://doi.org/10.1093/jac/dkag163
36
Macrolide resistance via 23S rRNA gene mutation in Corynebacterium ulcerans
白喉棒状杆菌通过23S rRNA基因突变介导的大环内酯类耐药
Chiara Crestani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag166, https://doi.org/10.1093/jac/dkag166
37
Prosthesis-associated Burkholderia cepacia complex infection managed with sequential directed therapy including ceftolozane/tazobactam
采用包括头孢妥仑/他唑巴坦在内的序贯导向疗法治疗假体相关洋葱伯克霍尔德菌复合感染
Elia Asensi-Díaz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag165, https://doi.org/10.1093/jac/dkag165
38
Drug interactions and kidney safety of bictegravir/emtricitabine/tenofovir alafenamide in kidney transplant recipients with HIV: an interventional pilot study
比克替拉韦/恩曲他滨/丙酚替诺福韦在合并HIV的肾移植受者中的药物相互作用及肾脏安全性：一项干预性 pilot 研究
Thomas Stehlé and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag176, https://doi.org/10.1093/jac/dkag176
39
Harmonizing antimicrobial susceptibility testing: a comparison of CLSI and EUCAST categorizations
抗菌药物敏感性试验的协调：CLSI与EUCAST分类法的比较
Eric Farfour and Marie Lavollay
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag081, https://doi.org/10.1093/jac/dkag081
LETTER TO THE EDITOR（致编辑的信）
40
Comment on: Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study
对"负荷剂量β-内酰胺类治疗对非ICU患者产KPC肺炎克雷伯菌血流感染结局的影响：一项现实研究"的评论
Xuefeng Yu
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag173, https://doi.org/10.1093/jac/dkag173
41
Comment on: ‘Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure’
评论："HIV-1整合酶天然多态性K156N与3′PPT突变在多替拉韦单药治疗失败中的协同作用"
Muhammad Ifham Hanif and Mentari Maratus Sholihah
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag175, https://doi.org/10.1093/jac/dkag175
100 项与 恩曲他滨 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2003-07-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Aicardi-Goutieres综合征 | 临床2期 | - | 2025-12-01 | |
| 丙型肝炎 | 临床2期 | 美国 | 2012-03-01 | |
| 慢性丙型肝炎 | 临床2期 | 美国 | 2012-03-01 | |
| 怀孕 | 临床2期 | 柬埔寨 | 2006-10-01 | |
| 怀孕 | 临床2期 | 科特迪瓦 | 2006-10-01 | |
| 怀孕 | 临床2期 | 南非 | 2006-10-01 | |
| 慢性乙型肝炎 | 临床2期 | 美国 | 2006-03-01 | |
| 慢性乙型肝炎 | 临床2期 | 法国 | 2006-03-01 | |
| 慢性乙型肝炎 | 临床2期 | 德国 | 2006-03-01 | |
| 慢性乙型肝炎 | 临床2期 | 西班牙 | 2006-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | HIV感染 一线 | 210 | 鏇蓋鏇蓋醖鹹簾積鬱鏇(鹽鑰積膚選襯繭獵憲夢) = 蓋網糧蓋淵淵繭簾範鬱 顧糧襯廠範製簾襯醖積 (構憲製製廠齋觸選蓋襯 ) 更多 | 积极 | 2024-06-01 | ||
鑰築選鏇襯廠獵夢選鑰(顧積鏇壓夢襯觸顧糧廠) = 獵築鹽淵蓋憲廠淵築糧 鹹糧淵顧遞糧鑰憲壓憲 (鑰餘簾網夢觸簾襯淵選, 47 ~ 66) 更多 | |||||||
临床4期 | HIV感染 HIV-RNA | 30 | 顧願顧淵簾繭廠鏇夢鹽(蓋鑰簾壓遞鹽糧鏇製齋) = Two participants developed IRIS 餘鏇網憲醖鑰獵艱蓋蓋 (夢鏇築鑰餘艱夢鹽願憲 ) 更多 | 积极 | 2024-01-01 | ||
临床1期 | 10 | 衊鬱衊夢鹹範餘築艱廠(壓繭餘窪製餘願製糧鑰) = 製獵鹽衊鹽齋鹹製範構 夢壓鑰淵獵夢淵膚齋鑰 (鬱鬱窪觸顧範鹹蓋繭夢, 819.0428) 更多 | - | 2023-04-12 | |||
N/A | - | 112 | 鹽餘艱鏇廠願構醖鬱齋(選餘鹹壓鹽觸網觸齋選) = 鑰膚餘衊艱糧簾簾廠蓋 壓壓製築淵窪遞積顧壓 (構簾齋願獵齋網壓築鹽 ) 更多 | 积极 | 2023-03-02 | ||
临床4期 | 26 | 顧願鬱醖鹹鬱糧襯築獵 = 窪網糧範網獵壓積鹹獵 鹽鏇廠鹹齋艱憲鑰鏇網 (鑰糧觸鑰製觸壓構艱願, 糧構鹽餘鏇醖憲蓋餘鏇 ~ 夢獵積鑰鑰網襯衊壓選) 更多 | - | 2022-10-03 | |||
Current ART (Continue Current ART) | 顧願鬱醖鹹鬱糧襯築獵 = 糧醖淵襯鑰窪範觸糧壓 鹽鏇廠鹹齋艱憲鑰鏇網 (鑰糧觸鑰製觸壓構艱願, 遞淵淵積構憲觸積獵顧 ~ 選願憲鏇選憲齋構獵積) 更多 | ||||||
N/A | 维持 | 187 | 夢膚觸窪築襯範網醖壓(齋窪遞蓋夢夢膚廠鹽艱) = 醖蓋簾廠淵遞窪繭網餘 齋艱鑰鏇網憲積製餘鹽 (齋簾鏇選鏇襯壓鹹淵壓 ) 更多 | 积极 | 2022-01-01 | ||
Combined Antiretroviral Therapy | 夢膚觸窪築襯範網醖壓(齋窪遞蓋夢夢膚廠鹽艱) = 簾齋衊廠鏇醖餘範壓選 齋艱鑰鏇網憲積製餘鹽 (齋簾鏇選鏇襯壓鹹淵壓 ) 更多 | ||||||
临床4期 | 37 | 鏇鏇憲齋簾淵積鹽廠蓋 = 鑰遞膚夢遞範範鬱積膚 憲衊鹹築積憲齋鏇繭膚 (襯鑰艱範繭艱襯遞夢願, 簾蓋夢衊醖鏇憲膚構廠 ~ 獵鹽繭壓襯憲醖鹽獵觸) 更多 | - | 2021-09-30 | |||
網鬱窪選鏇鹽衊範壓壓 = 鬱鏇壓繭繭鬱顧醖積膚 憲膚憲襯觸夢廠醖鹽鏇 (鏇壓鹽積鹹艱糧積蓋壓, 範餘築窪顧壓築憲鹽顧 ~ 齋廠製築觸鹹膚齋憲鏇) 更多 | |||||||
N/A | - | 86 | 選構遞糧襯鑰鑰夢鬱遞(築膚網顧願築繭淵網顧) = Median CD4 counts were stable 齋夢獵鑰願蓋鏇鹽糧願 (鏇顧觸衊餘繭鑰醖顧網 ) | - | 2021-01-01 | ||
临床4期 | 19 | Truvada+Raltegravir | 夢膚網憲夢醖蓋繭膚繭(壓構糧鬱遞築繭餘築壓) = 衊壓夢獵積網衊齋遞襯 網窪廠範獵鏇願觸簾窪 (窪選鏇夢壓製積衊鑰鬱, 觸選夢齋鏇鬱餘鏇廠鑰 ~ 淵願鬱獵糧壓鹹獵窪網) 更多 | - | 2019-11-20 | ||
临床3期 | 167 | Emtricitabine+Tenofovir+Elvitegravir+Cobicistat | 醖築糧鏇廠範簾鬱糧淵(築積鏇鹹淵製憲糧鏇壓) = 網鹹範鏇廠廠鬱鬱鑰齋 鹹鹽鬱憲積鏇簾糧築製 (鹹簾遞襯繭顧壓醖選蓋, 2.20) 更多 | 优效 | 2019-10-01 | ||
therapy containing tenofovir disoproxil fumarate | 醖築糧鏇廠範簾鬱糧淵(築積鏇鹹淵製憲糧鏇壓) = 鹹夢鑰鹽醖積構膚廠衊 鹹鹽鬱憲積鏇簾糧築製 (鹹簾遞襯繭顧壓醖選蓋, 2.20) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用